Search

Your search keyword '"Nieuwenhuijzen, G."' showing total 456 results
Start Over Author "Nieuwenhuijzen, G."
456 results on '"Nieuwenhuijzen, G."'

3. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk (“ugly”) locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT)

Author

van den Berg, K., Schaap, D. P., Voogt, E. L. K., Buffart, T. E., Verheul, H. M. W., de Groot, J. W. B., Verhoef, C., Melenhorst, J., Roodhart, J. M. L., de Wilt, J. H. W., van Westreenen, H. L., Aalbers, A. G. J., van ‘t Veer, M., Marijnen, C. A. M., Vincent, J., Simkens, L. H. J., Peters, N. A. J. B., Berbée, M., Werter, I. M., Snaebjornsson, P., Peulen, H. M. U., van Lijnschoten, I. G., Roef, M. J., Nieuwenhuijzen, G. A. P., Bloemen, J. G., Willems, J. M. W. E., Creemers, G. J. M., Nederend, J., Rutten, H. J. T., and Burger, J. W. A.

Published
2022
Full Text
View/download PDF

5. Cost-utility of an eHealth application ‘Oncokompas’ that supports cancer survivors in self-management: results of a randomised controlled trial

Author

van der Hout, A., Jansen, F., van Uden-Kraan, C. F., Coupé, V. M., Holtmaat, K., Nieuwenhuijzen, G. A., Hardillo, J. A., de Jong, R. J. Baatenburg, Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J. E., Bosscha, K., van den Brekel, M. W. M., Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, I., van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E. J., Leemans, C. R., Zijlstra, J. M., Cuijpers, P., van de Poll-Franse, L. V., and Verdonck-de Leeuw, I. M.

Published
2021
Full Text
View/download PDF

9. Paravertebral catheter versus EPidural analgesia in Minimally invasive Esophageal resectioN: a randomized controlled multicenter trial (PEPMEN trial)

Author

Kingma, B. F., Eshuis, W. J., de Groot, E. M., Feenstra, M. L., Ruurda, J. P., Gisbertz, S. S., ten Hoope, W., Marsman, M., Hermanides, J., Hollmann, M. W., Kalkman, C. J., Luyer, M. D. P., Nieuwenhuijzen, G. A. P., Scholten, H. J., Buise, M., van Det, M. J., Kouwenhoven, E. A., van der Meer, F., Frederix, G. W. J., Cheong, E., al Naimi, K., van Berge Henegouwen, M. I., and van Hillegersberg, R.

Published
2020
Full Text
View/download PDF

11. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe

Author

Kroese, T.E., Laarhoven, H.W.M. van, Schoppman, S.F., Deseyne, P., Cutsem, E. Van, Haustermans, K., Nafteux, P., Thomas, M., Obermannova, R., Mortensen, H.R., Nordsmark, M., Pfeiffer, P., Elme, A., Adenis, A., Piessen, G., Bruns, C.J., Lordick, F., Gockel, I., Moehler, M., Gani, C., Liakakos, T., Reynolds, J., Morganti, A.G., Rosati, R., Castoro, C., Cellini, F., D'Ugo, D., Roviello, F., Bencivenga, M., Manzoni, G. de, Henegouwen, M.I. van Berge, Hulshof, M., Dieren, J. van, Vollebergh, M., Sandick, J.W. van, Jeene, P., Muijs, C.T., Slingerland, M., Voncken, F.E.M., Hartgrink, H., Creemers, G.J., Sangen, M.J. van der, Nieuwenhuijzen, G., Berbee, M., Verheij, M., Wijnhoven, B., Beerepoot, L.V., Mohammad, N.H., Mook, S., Ruurda, J.P., Kolodziejczyk, P., Polkowski, W.P., Wyrwicz, L., Alsina, M., Pera, M., Kanonnikoff, T.F., Cervantes, A., Nilsson, M., Monig, S., Wagner, A.D., Guckenberger, M., Griffiths, E.A., Smyth, E., Hanna, G.B., Markar, S., Chaudry, M.A., Hawkins, M.A., Cheong, E., Rütten, H., Gootjes, E.C., Hillegersberg, R. van, Rossum, P.S.N. van, Kroese, T.E., Laarhoven, H.W.M. van, Schoppman, S.F., Deseyne, P., Cutsem, E. Van, Haustermans, K., Nafteux, P., Thomas, M., Obermannova, R., Mortensen, H.R., Nordsmark, M., Pfeiffer, P., Elme, A., Adenis, A., Piessen, G., Bruns, C.J., Lordick, F., Gockel, I., Moehler, M., Gani, C., Liakakos, T., Reynolds, J., Morganti, A.G., Rosati, R., Castoro, C., Cellini, F., D'Ugo, D., Roviello, F., Bencivenga, M., Manzoni, G. de, Henegouwen, M.I. van Berge, Hulshof, M., Dieren, J. van, Vollebergh, M., Sandick, J.W. van, Jeene, P., Muijs, C.T., Slingerland, M., Voncken, F.E.M., Hartgrink, H., Creemers, G.J., Sangen, M.J. van der, Nieuwenhuijzen, G., Berbee, M., Verheij, M., Wijnhoven, B., Beerepoot, L.V., Mohammad, N.H., Mook, S., Ruurda, J.P., Kolodziejczyk, P., Polkowski, W.P., Wyrwicz, L., Alsina, M., Pera, M., Kanonnikoff, T.F., Cervantes, A., Nilsson, M., Monig, S., Wagner, A.D., Guckenberger, M., Griffiths, E.A., Smyth, E., Hanna, G.B., Markar, S., Chaudry, M.A., Hawkins, M.A., Cheong, E., Rütten, H., Gootjes, E.C., Hillegersberg, R. van, and Rossum, P.S.N. van

Abstract

Item does not contain fulltext, BACKGROUND: Local treatment improves the outcomes for oligometastatic disease (OMD, i.e. an intermediate state between locoregional and widespread disseminated disease). However, consensus about the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer is lacking. The aim of this study was to develop a multidisciplinary European consensus statement on the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer. METHODS: In total, 65 specialists in the multidisciplinary treatment for oesophagogastric cancer from 49 expert centres across 16 European countries were requested to participate in this Delphi study. The consensus finding process consisted of a starting meeting, 2 online Delphi questionnaire rounds and an online consensus meeting. Input for Delphi questionnaires consisted of (1) a systematic review on definitions of oligometastatic oesophagogastric cancer and (2) a discussion of real-life clinical cases by multidisciplinary teams. Experts were asked to score each statement on a 5-point Likert scale. The agreement was scored to be either absent/poor (<50%), fair (50%-75%) or consensus (≥75%). RESULTS: A total of 48 experts participated in the starting meeting, both Delphi rounds, and the consensus meeting (overall response rate: 71%). OMD was considered in patients with metastatic oesophagogastric cancer limited to 1 organ with ≤3 metastases or 1 extra-regional lymph node station (consensus). In addition, OMD was considered in patients without progression at restaging after systemic therapy (consensus). For patients with synchronous or metachronous OMD with a disease-free interval ≤2 years, systemic therapy followed by restaging to consider local treatment was considered as treatment (consensus). For metachronous OMD with a disease-free interval >2 years, either upfront local treatment or systemic treatment followed by restaging was considered as treatment (fair agreement). CONCLUSION: The OMEC project has resul

Published
2023

12. Practice variation in anastomotic leak after esophagectomy: Unravelling differences in failure to rescue.

Author

Ubels, S., Matthée, E.P.C., Verstegen, M.H.P., Klarenbeek, B.R., Bouwense, S., Berge Henegouwen, M.I. van, Daams, F., Dekker, J.W.T., Det, M.J. van, Esser, S. van, Griffiths, E.A., Haveman, J.W., Nieuwenhuijzen, G., Siersema, P.D., Wijnhoven, B., Hannink, G.J., Workum, F.T.W.E. van, Rosman, C., Heisterkamp, J., Polat, F., Schouten, J.A., Singh, P., Ubels, S., Matthée, E.P.C., Verstegen, M.H.P., Klarenbeek, B.R., Bouwense, S., Berge Henegouwen, M.I. van, Daams, F., Dekker, J.W.T., Det, M.J. van, Esser, S. van, Griffiths, E.A., Haveman, J.W., Nieuwenhuijzen, G., Siersema, P.D., Wijnhoven, B., Hannink, G.J., Workum, F.T.W.E. van, Rosman, C., Heisterkamp, J., Polat, F., Schouten, J.A., and Singh, P.

Abstract

Item does not contain fulltext, INTRODUCTION: Failure to rescue (FTR) is an important outcome measure after esophagectomy and reflects mortality after postoperative complications. Differences in FTR have been associated with hospital resection volume. However, insight into how centers manage complications and achieve their outcomes is lacking. Anastomotic leak (AL) is a main contributor to FTR. This study aimed to assess differences in FTR after AL between centers, and to identify factors that explain these differences. METHODS: TENTACLE - Esophagus is a multicenter, retrospective cohort study, which included 1509 patients with AL after esophagectomy. Differences in FTR were assessed between low-volume (<20 resections), middle-volume (20-60 resections) and high-volume centers (≥60 resections). Mediation analysis was performed using logistic regression, including possible mediators for FTR: case-mix, hospital resources, leak severity and treatment. RESULTS: FTR after AL was 11.7%. After adjustment for confounders, FTR was lower in high-volume vs. low-volume (OR 0.44, 95%CI 0.2-0.8), but not versus middle-volume centers (OR 0.67, 95%CI 0.5-1.0). After mediation analysis, differences in FTR were found to be explained by lower leak severity, lower secondary ICU readmission rate and higher availability of therapeutic modalities in high-volume centers. No statistically significant direct effect of hospital volume was found: high-volume vs. low-volume 0.86 (95%CI 0.4-1.7), high-volume vs. middle-volume OR 0.86 (95%CI 0.5-1.4). CONCLUSION: Lower FTR in high-volume compared with low-volume centers was explained by lower leak severity, less secondary ICU readmissions and higher availability of therapeutic modalities. To reduce FTR after AL, future studies should investigate effective strategies to reduce leak severity and prevent secondary ICU readmission.

Published
2023

13. Treatment of anastomotic leak after oesophagectomy for oesophageal cancer: large, collaborative, observational TENTACLE cohort study.

Author

Ubels, S., Verstegen, M.H.P., Klarenbeek, B.R., Bouwense, S., Berge Henegouwen, M.I. van, Daams, F., Det, M.J. van, Griffiths, E.A., Haveman, J.W., Heisterkamp, J., Nieuwenhuijzen, G., Polat, F., Schouten, J.A., Siersema, P.D., Singh, P., Wijnhoven, B., Hannink, G.J., Workum, F.T.W.E. van, Rosman, C., Ubels, S., Verstegen, M.H.P., Klarenbeek, B.R., Bouwense, S., Berge Henegouwen, M.I. van, Daams, F., Det, M.J. van, Griffiths, E.A., Haveman, J.W., Heisterkamp, J., Nieuwenhuijzen, G., Polat, F., Schouten, J.A., Siersema, P.D., Singh, P., Wijnhoven, B., Hannink, G.J., Workum, F.T.W.E. van, and Rosman, C.

Abstract

Contains fulltext : 294540.pdf (Publisher’s version ) (Open Access), BACKGROUND: Anastomotic leak is a severe complication after oesophagectomy. Anastomotic leak has diverse clinical manifestations and the optimal treatment strategy is unknown. The aim of this study was to assess the efficacy of treatment strategies for different manifestations of anastomotic leak after oesophagectomy. METHODS: A retrospective cohort study was performed in 71 centres worldwide and included patients with anastomotic leak after oesophagectomy (2011-2019). Different primary treatment strategies were compared for three different anastomotic leak manifestations: interventional versus supportive-only treatment for local manifestations (that is no intrathoracic collections; well perfused conduit); drainage and defect closure versus drainage only for intrathoracic manifestations; and oesophageal diversion versus continuity-preserving treatment for conduit ischaemia/necrosis. The primary outcome was 90-day mortality. Propensity score matching was performed to adjust for confounders. RESULTS: Of 1508 patients with anastomotic leak, 28.2 per cent (425 patients) had local manifestations, 36.3 per cent (548 patients) had intrathoracic manifestations, 9.6 per cent (145 patients) had conduit ischaemia/necrosis, 17.5 per cent (264 patients) were allocated after multiple imputation, and 8.4 per cent (126 patients) were excluded. After propensity score matching, no statistically significant differences in 90-day mortality were found regarding interventional versus supportive-only treatment for local manifestations (risk difference 3.2 per cent, 95 per cent c.i. -1.8 to 8.2 per cent), drainage and defect closure versus drainage only for intrathoracic manifestations (risk difference 5.8 per cent, 95 per cent c.i. -1.2 to 12.8 per cent), and oesophageal diversion versus continuity-preserving treatment for conduit ischaemia/necrosis (risk difference 0.1 per cent, 95 per cent c.i. -21.4 to 1.6 per cent). In general, less morbidity was found after less extensive primary tre

Published
2023

15. Oncological Safety and Potential Cost Savings of Routine vs Selective Histopathological Examination After Appendectomy Results of the Multicenter, Prospective, Cross-Sectional FANCY Study

Author

Bastiaenen, Vivian P., de Jonge, Joske, Corten, Bartholomeus J. G. A., de Savornin Lohman, Elise A. J., Kraima, Anne C., Swank, Hilko A., van Vliet, Jaap L. P., van Acker, Gijs J. D., van Geloven, Anna A. W., in'tHof, Klaas H., Koens, Lianne, de Reuver, Philip R., van Rossem, Charles C., Slooter, Gerrit D., Tanis, Pieter J., Terpstra, Valeska, Dijkgraaf, Marcel G. W., Bemelman, Willem A., Amelung, F. J., Atema, J. J., Bessems, S., Beunders, A. A. M., Bodewes, T. C. F., den Boer, F. C., Boerma, D., Boerma, E. G., van den Boezem, P., Bökkerink, W. J. V., van den Boogaart, D., Boogerd, L. S. F., Bouwman, H., Broos, A., Brueren, L. O., Bruinsma, W. E., Bruns, E. R. C., Castelijns, P. S. S., de Castro, S. M. M., Consten, E. C. J., Crolla, R. M. P. H., Dam, M. J., Dang, Q., Dekker, J. W. T., Deroose, J. P., Devriendt, S., Dijkema, E. J., Dijkstra, N., Driessen, M. L. S., van Duijvendijk, P., Duinhouwer, L. E., van Duyn, E. B., el-Massoudi, Y., Elfrink, A. K. E., Elschot, J. H., van Essen, J. A., Ferenschild, F. T. J., Gans, S. L., Gaznay, C., Geraedts, A. C. M., van Gessel, B. S. H., Giesen, L. J. X., van Gils, N., Gorgec, B., Gorter, R. R., Govaert, K. M., Greuter, G. N., van Grevenstein, W. M. U., Groot, L., Hardy, J. C. A., Heemskerk, J., Heeren, J. F., Heidotting, J., Heikens, J. T., Hosseinzoi, E., van Iersel, J. J., Inberg, B., Jansen, L. J., Jens, A. J. T., Jilesen, A. P. J., Joosten, M., de Jong, L., Keijzers, M., Klicks, R. J., Kloppenberg, F. W. H., Koedam, T. W. A., Koëter, T., Konsten, J. L. M., Koolen, L. J. E. R., Kruyt, Ph. M., Lange, J. F. M., Lavrijssen, B. D. A., de Leede, E. M., Leliefeld, P. H. C., Linnemann, R. J. A., Lo, G. C., van de Loo, M., Lubbert, P. H. W., Holzik, M. F. Lutke, Manusama, E., Masselink, I., Matthée, E. P. C., Matthijsen, R. A., Mearadji, A., Melenhorst, J., Merkus, J. W. S., Michiels, T. D., Moes, D. E., Moossdorff, M., Mulder, E., Nallayici, E. G., Neijenhuis, P. A., Nielsen, K., Nieuwenhuijzen, G. A. P., Nijhuis, J., Okkema, S., Olthof, P. B., van Onkelen, R. S., van Oostendorp, S. E., Plaisier, P. W., Polle, S. W., Reiber, B. M. M., Reichert, F. C. M., van Rest, K. L. C., van Rijn, R., Roozendaal, N. C., de Ruijter, W. M. J., Schat, E., Scheerhoorn, J., Scheijmans, J. C. G., Schimmer, J., Schipper, R. J., Schouten, R., Schreurs, W. H., Schrijver, W. A. M. E., Shapiro, J., Siemons, A., Silvis, R., Simkens, G. A., Smakman, N., Smeets, B. J. J., Sonneveld, D. J. A., van Suijlichem, M., Talsma, A. K., Thoolen, J. M. M., van Tol, R. R., Tournoij, E., Tseng, L. N. L., Tuynman, J. B., van der Velde, K., Veltkamp, S. C., Verbeek, F. P. R., Verdaasdonk, E., Verhaak, T., Verheuvel, N. C., Vermaas, M., Verseveld, M., Vlek, S., Vogels, S., van de Voort, E. M. F., van Vugt, S. T., Wegdam, J. A., Wennekers, M. M., Wiering, B., de Wijkerslooth, E. M. L., Wijkmans, A. A., Wijnhoven, B. P. L., Witjes, C. D. M., Wolfhagen, N., de Zeeuw, S., van Zoonen, G., Surgery, Erasmus MC other, Obstetrics & Gynecology, Department of Strategic Management and Entrepreneurship, Neurology, Rotterdam School of Management, Cardiology, Gastroenterology & Hepatology, Radiology & Nuclear Medicine, Otorhinolaryngology and Head and Neck Surgery, Emergency Medicine, Public Health, Plastic and Reconstructive Surgery and Hand Surgery, Dermatology, Clinical Chemistry, Internal Medicine, Erasmus School of Social and Behavioural Sciences, General Practice, Radiotherapy, Research & Education, Rehabilitation Medicine, Urology, Pathology, Amsterdam Gastroenterology Endocrinology Metabolism, Cancer Center Amsterdam, Hematology laboratory, VU University medical center, CCA - Cancer Treatment and quality of life, and CCA - Imaging and biomarkers

Subjects
medicine.medical_specialty, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], All institutes and research themes of the Radboud University Medical Center, business.industry, General surgery, Medicine, Surgery, Histopathological examination, business, Cost savings
Abstract

Objective: To investigate the oncological safety and potential cost savings of selective histopathological examination after appendectomy. Background: The necessity of routine histopathological examination after appendectomy has been questioned, but prospective studies investigating the safety of a selective policy are lacking. Methods: In this multicenter, prospective, cross-sectional study, inspection and palpation of the (meso)appendix was performed by the surgeon in patients with suspected appendicitis. The surgeon's opinion on additional value of histopathological examination was reported before sending all specimens to the pathologist. Main outcomes were the number of hypothetically missed appendiceal neoplasms with clinical consequences benefiting the patient (upper limit two-sided 95% confidence interval below 3:1000 considered oncologically safe) and potential cost savings after selective histopathological examination. Results: Seven thousand three hundred thirty-nine patients were included. After a selective policy, 4966/7339 (67.7%) specimens would have been refrained from histopathological examination. Appendiceal neoplasms with clinical consequences would have been missed in 22/4966 patients. In 5/22, residual disease was completely resected during additional surgery. Hence, an appendiceal neoplasm with clinical consequences benefiting the patient would have been missed in 1.01:1000 patients (upper limit 95% confidence interval 1.61:1000). In contrast, twice as many patients (10/22) would not have been exposed to potential harm due to re-resections without clear benefit, whereas consequences were neither beneficial nor harmful in the remaining seven. Estimated cost savings established by replacing routine for selective histopathological examination were 725,400 per 10,000 patients. Conclusions: Selective histopathological examination after appendectomy for suspected appendicitis is oncologically safe and will likely result in a reduction of pathologists' workload, less costs, and fewer re-resections without clear benefit.

Published
2023

16. Ten-year outcomes of a randomised trial of laparoscopic versus open surgery for colon cancer

Author

Deijen, Charlotte L., Vasmel, Jeanine E., de Lange-de Klerk, Elly S. M., Cuesta, Miguel A., Coene, Peter-Paul L. O., Lange, Johan F., Meijerink, W. J. H. Jeroen, Jakimowicz, Jack J., Jeekel, Johannes, Kazemier, Geert, Janssen, Ignace M. C., Påhlman, Lars, Haglind, Eva, Bonjer, H. Jaap, Hellberg, R., Haglind, E., Kurlberg, G., Lindgren, P. G., Lindholm, E., Påhlman, L., Dahlberg, M., Raab, Y., Anderberg, B., Ewerth, S., Janson, M., Åkerlund, J. E., Smedh, K., Montgomery, A., Skullman, S., Nyström, P. O., Kald, A., Wänström, A., Dàlen, J., Svedberg, I., Edlund, G., Kressner, U., Öberg, A. N., Lundberg, O., Lindmark, G. E., Heikkinen, T., Morino, M., Giraudo, G., Lacy, A. M., Delgado, S., Macarulla Sanz, E., Díez, J. Medina, Schwandner, O., Schiedeck, T. H., Shekarriz, H., Bloechle, C., Baca, I., Weiss, O., Msika, S., Desvignes, G., Campbell, K. L., Cuschieri, A., Bonjer, H. J., Schouten, W. R., Kazemier, G., Lange, J. F., van der Harst, E., Coene, P. P. L. O., Plaisier, P., Bertleff, M. J. O. E., Cuesta, M. A., van der Broek, W., Meijerink, W. J. H. J., Jakimowicz, J. J., Nieuwenhuijzen, G., Maring, J., Kivit, J., Janssen, I. M. C., Spillenaar-Bilgen, E. J., Berends, F., and On behalf of the COLOR (COlon cancer Laparoscopic or Open Resection) study group

Published
2017
Full Text
View/download PDF

17. Using the Comprehensive Complication Index to Assess the Impact of Neoadjuvant Chemoradiotherapy on Complication Severity After Esophagectomy for Cancer

Author

Nederlof, Nina, Slaman, Annelijn E., van Hagen, Pieter, van der Gaast, Ate, Slankamenac, Ksenija, Gisbertz, Suzanne S., van Lanschot, Jan J. B., Wijnhoven, Bas P. L., van Berge Henegouwen, Mark I., Bonenkamp, J. J., Busch, O. R. C., Cuesta, M. A., Nieuwenhuijzen, G. A. P., Plukker, J. T. M., Spillenaar Bilgen, E. J., Tilanus, H. W., and CROSS-Study Group

Published
2016
Full Text
View/download PDF

18. Simultaneous pelvic exenteration and liver resection for primary rectal cancer with synchronous liver metastases: results from the PelvEx Collaborative

Author

Kelly, M. E., Aalbers, A. G. J., Abdul Aziz, N., Abecasis, N., Abraham‐Nordling, M., Akiyoshi, T., Alberda, W., Albert, M., Andric, M., Angenete, E., Antoniou, A., Auer, R., Austin, K. K., Aziz, O., Baker, R. P., Bali, M., Baseckas, G., Bebington, B., Bednarski, B. K., Beets, G. L., Berg, P. L., Beynon, J., Biondo, S., Boyle, K., Bordeianou, L., Bremers, A. B., Brunner, M., Buchwald, P., Bui, A., Burgess, A., Burger, J. W. A., Burling, D., Burns, E., Campain, N., Carvalhal, S., Castro, L., Caycedo‐Marulanda, A., Chan, K. K. L., Chang, G. J., Chew, M. H., Chong, P. C., Christensen, H. K., Clouston, H., Codd, M., Collins, D., Colquhoun, A. J., Corr, A., Coscia, M., Coyne, P. E., Creavin, B., Croner, R. S., Damjanovic, L., Daniels, I. R., Davies, M., Davies, R. J., Delaney, C. P., Denost, Q., Deutsch, C., Dietz, D., Domingo, S., Dozois, E. J., Duff, M., Eglinton, T., Enrique‐Navascues, J. M., Espin‐Basany, E., Evans, M. D., Fearnhead, N. S., Flatmark, K., Fleming, F., Frizelle, F. A., Gallego, M. A., Garcia‐Granero, E., Garcia‐Sabrido, J. L., Gentilini, L., George, M. L., Ghouti, L., Giner, F., Ginther, N., Glynn, R., Golda, T., Griffiths, B., Harris, D. A., Hagemans, J. A. W., Hanchanale, V., Harji, D. P., Helewa, R. M., Heriot, A. G., Hochman, D., Hohenberger, W., Holm, T., Hompes, R., Jenkins, J. T., Kaffenberger, S., Kandaswamy, G. V., Kapur, S., Kanemitsu, Y., Kelley, S. R., Keller, D. S., Khan, M. S., Kiran, R. P., Kim, H., Kim, H. J., Koh, C. E., Kok, N. F. M., Kokelaar, R., Kontovounisios, C., Kristensen, H. Ø., Kroon, H. M., Kusters, M., Lago, V., Larsen, S. G., Larson, D. W., Law, W. L., Laurberg, S., Lee, P. J., Limbert, M., Lydrup, M. L., Lyons, A., Lynch, A. C., Mantyh, C., Mathis, K. L., Margues, C. F. S., Martling, A., Meijerink, W. J. H. J., Merkel, S., Mehta, A. M., McArthur, D. R., McDermott, F. D., McGrath, J. S., Malde, S., Mirnezami, A., Monson, J. R. T., Morton, J. R., Mullaney, T. G., Negoi, I., Neto, J. W. M., Nguyen, B., Nielsen, M. B., Nieuwenhuijzen, G. A. P., Nilsson, P. J., O’Connell, P. R., O’Dwyer, S. T., Palmer, G., Pappou, E., Park, J., Patsouras, D., Pellino, G., Peterson, A. C., Poggioli, G., Proud, D., Quinn, M., Quyn, A., Radwan, R. W., van Ramshorst, G. H., Rasheed, S., Rasmussen, P. C., Regenbogen, S. E., Renehan, A., Rocha, R., Rochester, M., Rohila, J., Rothbarth, J., Rottoli, M., Roxburgh, C., Rutten, H. J. T., Ryan, É. J., Safar, B., Sagar, P. M., Sahai, A., Saklani, A., Sammour, T., Sayyed, R., Schizas, A. M. P., Schwarzkopf, E., Scripcariu, V., Selvasekar, C., Shaikh, I., Hellawell, G., Shida, D., Simpson, A., Smart, N. J., Smart, P., Smith, J. J., Solbakken, A. M., Solomon, M. J., Sørensen, M. M., Steele, S. R., Steffens, D., Stitzenberg, K., Stocchi, L., Stylianides, N. A., Sumrien, H., Sutton, P. A., Swartking, T., Taylor, C., Tekkis, P. P., Teras, J., Thurairaja, R., Toh, E. L., Tsarkov, P., Tsukada, Y., Tsukamoto, S., Tuech, J. J., Turner, W. H., Tuynman, J. B., Vasquez‐Jimenez, W., Verhoef, C., Vizzielli, G., Voogt, E. L. K., Uehara, K., Wakeman, C., Warrier, S., Wasmuth, H. H., Weber, K., Weiser, M. R., Wheeler, J. M. D., Wild, J., Wilson, M., de Wilt, J. H. W., Wolthuis, A., Yano, H., Yip, B., Yip, J., Yoo, R. N., van Zoggel, D., Winter, D. C., Kelly, M. E., Aalbers, A. G. J., Abdul Aziz, N., Abecasis, N., Abraham‐nordling, M., Akiyoshi, T., Alberda, W., Albert, M., Andric, M., Angenete, E., Antoniou, A., Auer, R., Austin, K. K., Aziz, O., Baker, R. P., Bali, M., Baseckas, G., Bebington, B., Bednarski, B. K., Beets, G. L., Berg, P. L., Beynon, J., Biondo, S., Boyle, K., Bordeianou, L., Bremers, A. B., Brunner, M., Buchwald, P., Bui, A., Burgess, A., Burger, J. W. A., Burling, D., Burns, E., Campain, N., Carvalhal, S., Castro, L., Caycedo‐marulanda, A., Chan, K. K. L., Chang, G. J., Chew, M. H., Chong, P. C., Christensen, H. K., Clouston, H., Codd, M., Collins, D., Colquhoun, A. J., Corr, A., Coscia, M., Coyne, P. E., Creavin, B., Croner, R. S., Damjanovic, L., Daniels, I. R., Davies, M., Davies, R. J., Delaney, C. P., Denost, Q., Deutsch, C., Dietz, D., Domingo, S., Dozois, E. J., Duff, M., Eglinton, T., Enrique‐navascues, J. M., Espin‐basany, E., Evans, M. D., Fearnhead, N. S., Flatmark, K., Fleming, F., Frizelle, F. A., Gallego, M. A., Garcia‐granero, E., Garcia‐sabrido, J. L., Gentilini, L., George, M. L., Ghouti, L., Giner, F., Ginther, N., Glynn, R., Golda, T., Griffiths, B., Harris, D. A., Hagemans, J. A. W., Hanchanale, V., Harji, D. P., Helewa, R. M., Heriot, A. G., Hochman, D., Hohenberger, W., Holm, T., Hompes, R., Jenkins, J. T., Kaffenberger, S., Kandaswamy, G. V., Kapur, S., Kanemitsu, Y., Kelley, S. R., Keller, D. S., Khan, M. S., Kiran, R. P., Kim, H., Kim, H. J., Koh, C. E., Kok, N. F. M., Kokelaar, R., Kontovounisios, C., Kristensen, H. Ø., Kroon, H. M., Kusters, M., Lago, V., Larsen, S. G., Larson, D. W., Law, W. L., Laurberg, S., Lee, P. J., Limbert, M., Lydrup, M. L., Lyons, A., Lynch, A. C., Mantyh, C., Mathis, K. L., Margues, C. F. S., Martling, A., Meijerink, W. J. H. J., Merkel, S., Mehta, A. M., Mcarthur, D. R., Mcdermott, F. D., Mcgrath, J. S., Malde, S., Mirnezami, A., Monson, J. R. T., Morton, J. R., Mullaney, T. G., Negoi, I., Neto, J. W. M., Nguyen, B., Nielsen, M. B., Nieuwenhuijzen, G. A. P., Nilsson, P. J., O’Connell, P. R., O’Dwyer, S. T., Palmer, G., Pappou, E., Park, J., Patsouras, D., Pellino, G., Peterson, A. C., Poggioli, G., Proud, D., Quinn, M., Quyn, A., Radwan, R. W., van Ramshorst, G. H., Rasheed, S., Rasmussen, P. C., Regenbogen, S. E., Renehan, A., Rocha, R., Rochester, M., Rohila, J., Rothbarth, J., Rottoli, M., Roxburgh, C., Rutten, H. J. T., Ryan, É. J., Safar, B., Sagar, P. M., Sahai, A., Saklani, A., Sammour, T., Sayyed, R., Schizas, A. M. P., Schwarzkopf, E., Scripcariu, V., Selvasekar, C., Shaikh, I., Hellawell, G., Shida, D., Simpson, A., Smart, N. J., Smart, P., Smith, J. J., Solbakken, A. M., Solomon, M. J., Sørensen, M. M., Steele, S. R., Steffens, D., Stitzenberg, K., Stocchi, L., Stylianides, N. A., Sumrien, H., Sutton, P. A., Swartking, T., Taylor, C., Tekkis, P. P., Teras, J., Thurairaja, R., Toh, E. L., Tsarkov, P., Tsukada, Y., Tsukamoto, S., Tuech, J. J., Turner, W. H., Tuynman, J. B., Vasquez‐jimenez, W., Verhoef, C., Vizzielli, G., Voogt, E. L. K., Uehara, K., Wakeman, C., Warrier, S., Wasmuth, H. H., Weber, K., Weiser, M. R., Wheeler, J. M. D., Wild, J., Wilson, M., de Wilt, J. H. W., Wolthuis, A., Yano, H., Yip, B., Yip, J., Yoo, R. N., van Zoggel, D., Winter, D. C., Kelly, ME, Aalbers, AGJ, Aziz, NA, Abecasis, N, Abraham-Nordling, M, Akiyoshi, T, Alberda, W, Albert, M, Andric, M, Angenete, E, Antoniou, A, Auer, R, Austin, KK, Aziz, O, Baker, RP, Bali, M, Baseckas, G, Bebington, B, Bednarski, BK, Beets, GL, Berg, PL, Beynon, J, Biondo, S, Boyle, K, Bordeianou, L, Bremers, AB, Brunner, M, Buchwald, P, Bui, A, Burgess, A, Burger, JWA, Burling, D, Burns, E, Campain, N, Carvalhal, S, Castro, L, Caycedo-Marulanda, A, Chan, KKL, Chew, GJH, Chong, PC, Christensen, HK, Clouston, H, Codd, M, Coffins, D, Colquhoun, AJ, Corr, A, Coscia, M, Coyne, PE, Creavin, B, Croner, RS, Damjanovic, L, Daniels, R, Davies, M, Davies, RJ, Delaney, CP, Denost, Q, Deutsch, C, Dietz, D, Domingo, S, Dozois, EJ, Duff, M, Eglinton, T, Enrique-Navascues, JM, Espin-Basany, E, Evans, MD, Fearnhead, NS, Flatmark, K, Fleming, F, Frizelle, FA, Gallego, MA, Garcia-Granero, E, Garcia-Sabrido, JL, Gentilini, L, George, ML, Ghouti, L, Giner, F, Ginther, N, Glynn, R, Golda, T, Griffiths, B, Harris, DA, Hagemans, JAW, Hanchanale, V, Harji, DP, Helewa, RM, Heriot, AG, Hochman, D, Hohenberger, W, Holm, T, Hompes, R, Jenkins, JT, Kaffenberger, S, Kandaswamy, GV, Kapur, S, Kanemitsu, Y, Kelley, SR, Keller, DS, Khan, MS, Kiran, RP, Kim, H, Kim, HJ, Koh, CE, Kok, NFM, Kokelaar, R, Kontovounisios, C, Kristensen, HO, Kroon, HM, Kusters, M, Lago, V, Larsen, SG, Larson, DW, Law, WL, Laurberg, S, Lee, PJ, Limbert, M, Lydrup, ML, Lyons, A, Lynch, AC, Mantyh, C, Mathis, KL, Margues, CFS, Martling, A, Meijerink, WJHJ, Merkel, S, Mehta, AM, McArthur, DR, McDermott, FD, McGrath, JS, Malde, S, Mimezami, A, Monson, JRT, Morton, JR, Mullaney, TG, Negoi, I, Neto, JWM, Nguyen, B, Nielsen, MB, Nieuwenhuijzen, GAP, Nilsson, PJ, O'Connell, PR, O'Dwyer, ST, Palmer, G, Pappou, E, Park, J, Patsouras, D, Pellino, G, Peterson, AC, Poggioli, G, Proud, D, Quinn, M, Quyn, A, Radwan, RW, van Ramshorst, GH, Rasheed, S, Rasmussen, PC, Regenbogen, SE, Renehan, A, Rocha, R, Rochester, M, Rohila, J, Rothbarth, J, Rottoli, M, Roxburgh, C, Rutten, HJT, Ryan, EJ, Safar, B, Sagar, PM, Sahai, A, Saklani, A, Sammour, T, Sayyed, R, Schizas, AMP, Schwarzkopf, E, Scripcariu, V, Selvasekar, C, Shaikh, I, Hellawell, G, Shida, D, Simpson, A, Smart, NJ, Smart, P, Smith, JJ, Solbakken, AM, Solomon, MJ, Sorensen, MM, Steele, SR, Steffens, D, Stitzenberg, K, Stocchi, L, Stylianides, NA, Sumrien, H, Sutton, PA, Swanking, T, Taylor, C, Tekkis, PP, Teras, J, Thurairaja, R, Toh, EL, Tsarkov, P, Tsukada, Y, Tsukamoto, S, Tuech, JJ, Turner, WH, Tuynman, JB, Vasquez-Jimenez, W, Verhoef, C, Vizzielli, G, Voogt, ELK, Uehara, K, Wakeman, C, Warner, S, Wasmuth, HH, Weber, K, Weiser, MR, Wheeler, JMD, Wild, J, Wilson, M, de Wilt, JHW, Wolthuis, A, Yano, H, Yip, B, Yip, J, Yoo, RN, van Zoggel, D, Winter, DC, Surgery, CCA - Cancer Treatment and quality of life, and Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
Male, medicine.medical_specialty, Adolescent, Colorectal cancer, survival outcomes, medicine.medical_treatment, surgical outcome, surgical outcomes, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, Interquartile range, medicine, Humans, liver metastasi, Rectal cancer, Retrospective Studies, Pelvic exenteration, business.industry, Rectal Neoplasms, Mortality rate, Liver Neoplasms, Gastroenterology, Postoperative complication, Perioperative, medicine.disease, Surgery, Pelvic Exenteration, liver metastasis, Treatment Outcome, 030220 oncology & carcinogenesis, international collaboration, Resection margin, 030211 gastroenterology & hepatology, Hepatectomy, Neoplasm Recurrence, Local, business
Abstract

Aim: At presentation, 15–20% of patients with rectal cancer already have synchronous liver metastases. The aim of this study was to determine the surgical and survival outcomes in patients with advanced rectal cancer who underwent combined pelvic exenteration and liver (oligometastatic) resection. Method: Data from 20 international institutions that performed simultaneous pelvic exenteration and liver resection between 2007 and 2017 were accumulated. Primarily, we examined perioperative outcomes, morbidity and mortality. We also assessed the impact that margin status had on survival. Results: Of 128 patients, 72 (56.2%) were men with a median age of 60 years [interquartile range (IQR) 15 years]. The median size of the liver oligometastatic deposits was 2 cm (IQR 1.8 cm). The median duration of surgery was 406 min (IQR 240 min), with a median blood loss of 1090 ml (IQR 2010 ml). A negative resection margin (R0 resection) was achieved in 73.5% of pelvic exenterations and 66.4% of liver resections. The 30-day mortality rate was 1.6%, and 32% of patients had a major postoperative complication. The 5-year overall survival for patients in whom an R0 resection of both primary and metastatic disease was achieved was 54.6% compared with 20% for those with an R1/R2 resection (P = 0.006). Conclusion: Simultaneous pelvic exenteration and liver resection is feasible, with acceptable morbidity and mortality. Simultaneous resection should only be performed where an R0 resection of both pelvic and hepatic disease is anticipated.

Published
2020

20. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial

Author

Noordman, B J, Verdam, M G E, Lagarde, S M, Shapiro, J, Hulshof, M C C M, van Berge Henegouwen, M I, Wijnhoven, B P L, Nieuwenhuijzen, G A P, Bonenkamp, J J, Cuesta, M A, Plukker, J Th M, Spillenaar Bilgen, E J, Steyerberg, E W, van der Gaast, A, Sprangers, M A G, and van Lanschot, J J B

Published
2018
Full Text
View/download PDF

21. Evaluation of PET and laparoscopy in STagIng advanced gastric cancer: a multicenter prospective study (PLASTIC-study)

Author

Brenkman, H. J. F., Gertsen, E. C., Vegt, E., van Hillegersberg, R., van Berge Henegouwen, M. I., Gisbertz, S. S., Luyer, M. D. P., Nieuwenhuijzen, G. A. P., van Lanschot, J. J. B., Lagarde, S. M., de Steur, W. O., Hartgrink, H. H., Stoot, J. H. M. B., Hulsewe, K. W. E., Spillenaar Bilgen, E. J., van Det, M. J., Kouwenhoven, E. A., van der Peet, D. L., Daams, F., van Sandick, J. W., van Grieken, N. C. T., Heisterkamp, J., van Etten, B., Haveman, J. W., Pierie, J. P., Jonker, F., Thijssen, A. Y., Belt, E. J. T., van Duijvendijk, P., Wassenaar, E., van Laarhoven, H. W. M., Wessels, F. J., Haj Mohammad, N., van Stel, H. F., Frederix, G. W. J., Siersema, P. D., Ruurda, J. P., and on behalf of the PLASTIC Study Group

Published
2018
Full Text
View/download PDF

24. Contemporary management of locally advanced and recurrent rectal cancer: views from the PelvEx collaborative

Author

Kelly M. E., O’Sullivan N. J., Fahy M. R., Aalbers A. G. J., Abdul Aziz N., Abecasis N., Abraham-Nordling M., Abu Saadeh F., Akiyoshi T., Alberda W., Albert M., Andric M., Angeles M. A., Angenete E., Antoniou A., Auer R., Austin K. K., Aytac E., Aziz O., Bacalbasa N., Baker R. P., Bali M., Baransi S., Baseckas G., Bebington B., Bedford M., Bednarski B. K., Beets G. L., Berg P. L., Bergzoll C., Beynon J., Biondo S., Boyle K., Bordeianou L., Brecelj E., Bremers A. B., Brunner M., Buchwald P., Bui A., Burgess A., Burger J. W. A., Burling D., Burns E., Campain N., Carvalhal S., Castro L., Caycedo-Marulanda A., Ceelen W., Chan K. K. L., Chang G. J., Chang M., Chew M. H., Chok A. Y., Chong P., Clouston H., Codd M., Collins D., Colquhoun A. J., Constantinides J., Corr A., Coscia M., Cosimelli M., Cotsoglou C., Coyne P. E., Croner R. S., Damjanovich L., Daniels I. R., Davies M., Delaney C. P., de Wilt J. H. W., Denost Q., Deutsch C., Dietz D., Domingo S., Dozois E. J., Drozdov E., Duff M., Eglinton T., Enriquez-Navascues J. M., Espín-Basany E., Evans M. D., Eyjólfsdóttir B., Fearnhead N. S., Ferron G., Fichtner-Feigl S., Flatmark K., Fleming F. J., Flor B., Folkesson J., Frizelle F. A., Funder J., Gallego M. A., Gargiulo M., García-Granero E., García-Sabrido J. L., Gava V. G., Gentilini L., George M. L., George V., Georgiou P., Ghosh A., Ghouti L., Gil-Moreno A., Giner F., Ginther D. N., Glyn T., Glynn R., Golda T., Griffiths B., Harris D. A., Hanchanale V., Harji D. P., Harris C., Helewa R. M., Hellawell G., Heriot A. G., Hochman D., HohenbergerW., Holm T., Hompes R., Hornung B., Hurton S., Hyun E., Ito M., Iversen L. H., Jenkins J. T., Jourand K., Kaffenberger S., Kandaswamy G. V., Kapur S., Kanemitsu Y., Kazi M., Kelley S. R., Keller D. S., Ketelaers S. H. J., Khan M. S., Kiran R. P., Kim H., Kim H. J., Koh C. E., Kok N. F. M., Kokelaar R., Kontovounisios C., Kose F., Koutra M., Kristensen H. Ø., Kroon H. M., Kumar S., Kusters M., Lago V., Lampe B., Lakkis Z., Larach J. T., Larkin J. O., Larsen S. G., Larson D. W., Law W. L., Lee P. J., Limbert M., Loria A., Lydrup ML., Lyons A., Lynch A. C., Maciel J., Manfredelli S., Mann C., Mantyh C., Mathis K. L., Marques C. F. S., Martinez A., Martling A., Mehigan B. J., MeijerinkW. J. H. J., Merchea A., Merkel S., Mehta A. M., Mikalauskas S., McArthur D. R., McCormick J. J., McCormick P., McDermott F. D., McGrath J. S., Malde S., Mirnezami A., Monson J. R. T., Navarro A. S., Neeff H., Negoi I., Neto J. W. M., Ng J. L., Nguyen B., Nielsen M. B., Nieuwenhuijzen G. A. P., Nilsson P. J., Nordkamp S., Nugent T., Oliver A., O’Dwyer S. T., Paarnio K., Palmer G., Pappou E., Park J., Patsouras D., Peacock O., Pellino G., Peterson A. C., Pfeffer F., Pinson J., Poggioli G., Proud D., Quinn M., Quyn A., Rajendran N., Radwan R. W., Rao C., Rasheed S., Rausa E., Regenbogen S. E., Reims H. M., Renehan A., Rintala J., Rocha R., Rochester M., Rohila J., Rothbarth J., Rottoli M., Roxburgh C., Rutten H. J. T., Safar B., Sagar P. M., Sahai A., Saklani A., Sammour T., Sayyed R., Schizas A. M. P., Schwarzkopf E., Scripcariu D., Scripcariu V., Selvasekar C., Shaikh I., Simpson A., Skeie-Jensen T., Smart N. J., Smart P., Smith J. J., Solbakken A. M., Solomon M. J., Sørensen M. M., Sorrentino L., Steele S. R., Steffens D., Stitzenberg K., Stocchi L., Stylianides N. A., Swartling T., Spasojevic M., Sumrien H., Sutton P. A., Swartking T., Takala H., Tan E. J., Taylor C., Taylor D., Tekin A., Tekkis P. P., Teras J., Thaysen H. V., Thurairaja R., Thorgersen E. B., Tiernan J., Toh E. L., Tolenaar J., Tsarkov P., Tsukada Y., Tsukamoto S., Tuech J. J., Turner W. H., Tuynman J. B., Valente M., van Ramshorst G. H., van Rees J., van Zoggel D., Vasquez-JimenezW., Vather R., Verhoef C., Vierimaa M., Vizzielli G., Voogt E. L. K., Uehara K., Urrejola G., Wakeman C., Warrier S. K., Wasmuth H. H., Waters P. S., Weber K., Weiser M. R., Wheeler J. M. D., Wild J., Williams A., Wilson M., Wolthuis A., Yano H., Yip B., Yoo R. N., Zappa M. A., Winter D. C., and Kelly M.E., O’Sullivan N.J., Fahy M.R., Aalbers A.G.J., Abdul Aziz N., Abecasis N., Abraham-Nordling M., Abu Saadeh F., Akiyoshi T., Alberda W., Albert M., Andric M., Angeles M.A., Angenete E., Antoniou A., Auer R., Austin K.K., Aytac E., Aziz O., Bacalbasa N., Baker R.P., Bali M., Baransi S., Baseckas G., Bebington B., Bedford M., Bednarski B.K., Beets G.L., Berg P.L., Bergzoll C., Beynon J., Biondo S., Boyle K., Bordeianou L., Brecelj E., Bremers A.B., Brunner M., Buchwald P., Bui A., Burgess A., Burger J.W.A., Burling D., Burns E., Campain N., Carvalhal S., Castro L., Caycedo-Marulanda A., Ceelen W., Chan K.K.L., Chang G.J., Chang M., Chew M.H., Chok A.Y., Chong P., Clouston H., Codd M., Collins D., Colquhoun A.J., Constantinides J., Corr A., Coscia M., Cosimelli M., Cotsoglou C., Coyne P.E., Croner R.S., Damjanovich L., Daniels I.R., Davies M., Delaney C.P., de Wilt J.H.W., Denost Q., Deutsch C., Dietz D., Domingo S., Dozois E.J., Drozdov E., Duff M., Eglinton T., Enriquez-Navascues J.M., Espín-Basany E., Evans M.D., Eyjólfsdóttir B., Fearnhead N.S., Ferron G., Fichtner-Feigl S., Flatmark K., Fleming F.J., Flor B., Folkesson J., Frizelle F.A., Funder J., Gallego M.A., Gargiulo M., García-Granero E., García-Sabrido J.L., Gargiulo M., Gava V.G., Gentilini L., George M.L., George V., Georgiou P., Ghosh A., Ghouti L., Gil-Moreno A., Giner F., Ginther D.N., Glyn T., Glynn R., Golda T., Griffiths B., Harris D.A., Hanchanale V., Harji D.P., Harris C., Helewa R.M., Hellawell G., Heriot A.G., Hochman D., HohenbergerW., Holm T., Hompes R., Hornung B., Hurton S., Hyun E., Ito M., Iversen L.H., Jenkins J.T., Jourand K., Kaffenberger S., Kandaswamy G.V., Kapur S., Kanemitsu Y., Kazi M., Kelley S.R., Keller D.S., Ketelaers S.H.J., Khan M.S., Kiran R.P., Kim H., Kim H.J., Koh C.E., Kok N.F.M., Kokelaar R., Kontovounisios C., Kose F., Koutra M., Kristensen H.Ø., Kroon H.M., Kumar S., Kusters M., Lago V., Lampe B., Lakkis Z., Larach J.T., Larkin J.O., Larsen S.G., Larson D.W., Law W.L., Lee P.J., Limbert M., Loria A., Lydrup ML., Lyons A., Lynch A.C., Maciel J., Manfredelli S., Mann C., Mantyh C., Mathis K.L., Marques C.F.S., Martinez A., Martling A., Mehigan B.J., MeijerinkW.J.H.J., Merchea A., Merkel S., Mehta A.M., Mikalauskas S., McArthur D.R., McCormick J.J., McCormick P., McDermott F.D., McGrath J.S., Malde S., Mirnezami A., Monson J.R.T., Navarro A.S., Neeff H., Negoi I., Neto J.W.M., Ng J.L., Nguyen B., Nielsen M.B., Nieuwenhuijzen G.A.P., Nilsson P.J., Nordkamp S., Nugent T., Oliver A., O’Dwyer S.T., Paarnio K., Palmer G., Pappou E., Park J., Patsouras D., Peacock O., Pellino G., Peterson A.C., Pfeffer F., Pinson J., Poggioli G., Proud D., Quinn M., Quyn A., Rajendran N., Radwan R.W., Rajendran N., Rao C., Rasheed S., Rausa E., Regenbogen S.E., Reims H.M., Renehan A., Rintala J., Rocha R., Rochester M., Rohila J., Rothbarth J., Rottoli M., Roxburgh C., Rutten H.J.T., Safar B., Sagar P.M., Sahai A., Saklani A., Sammour T., Sayyed R., Schizas A.M.P., Schwarzkopf E., Scripcariu D., Scripcariu V., Selvasekar C., Shaikh I., Simpson A., Skeie-Jensen T., Smart N.J., Smart P., Smith J.J., Solbakken A.M., Solomon M.J., Sørensen M.M., Sorrentino L., Steele S.R., Steffens D., Stitzenberg K., Stocchi L., Stylianides N.A., Swartling T., Spasojevic M., Sumrien H., Sutton P.A., Swartking T., Takala H., Tan E.J., Taylor C., Taylor D., Tekin A., Tekkis P.P., Teras J., Thaysen H.V., Thurairaja R., Thorgersen E.B., Tiernan J., Toh E.L., Tolenaar J., Tsarkov P., Tsukada Y., Tsukamoto S., Tuech J.J., Turner W.H., Tuynman J.B., Valente M., van Ramshorst G.H., van Rees J., van Zoggel D., Vasquez-JimenezW., Vather R., Verhoef C., Vierimaa M., Vizzielli G., Voogt E.L.K., Uehara K., Urrejola G., Wakeman C., Warrier S.K.,Wasmuth H.H.,Waters P.S.,Weber K.,Weiser M.R., Wheeler J.M.D.,Wild J., Williams A., Wilson M., Wolthuis A., Yano H., Yip B., Yoo R.N., Zappa M.A., Winter D.C.

Subjects
Cancer Research, perioperative care, ENHANCED RECOVERY, diagnostic, EXENTERATION, surgical management, surgical outcomes, recurrent rectal cancer, SDG 3 - Good Health and Well-being, locally advanced rectal cancer, QUALITY-OF-LIFE, Medicine and Health Sciences, diagnostics, 1112 Oncology and Carcinogenesis, PATHOLOGICAL COMPLETE RESPONSE, rectal cancer, SURGICAL TECHNIQUES, OUTCOMES, Science & Technology, HYPERTHERMIC INTRAPERITONEAL, PelvEx Collaborative, CHEMOTHERAPY, WHOLE-BODY MRI, NEOADJUVANT CHEMORADIOTHERAPY, Oncology, quality of life, CYTOREDUCTIVE SURGERY, HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY, Life Sciences & Biomedicine
Abstract

Pelvic exenteration is a complex operation performed for locally advanced and recurrent pelvic cancers. The goal of surgery is to achieve clear margins, therefore identifying adjacent or involved organs, bone, muscle, nerves and/or vascular structures that may need resection. While these extensive resections are potentially curative, they can be associated with substantial morbidity. Recently, there has been a move to centralize care to specialized units, as this facilitates better multidisciplinary care input. Advancements in pelvic oncology and surgical innovation have redefined the boundaries of pelvic exenterative surgery. Combined with improved neoadjuvant therapies, advances in diagnostics, and better reconstructive techniques have provided quicker recovery and better quality of life outcomes, with improved survival This article provides highlights of the current management of advanced pelvic cancers in terms of surgical strategy and potential future developments.

Published
2022

25. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe

Author

Kroese, T.E., Hillegersberg, R. van, Schoppmann, S., Deseyne, P., Nafteux, P., Obermannova, R., Nordsmark, M., Pfeiffer, P., Hawkins, M.A., Smyth, E., Markar, S., Hanna, G.B., Cheong, E., Chaudry, A., Elme, A., Adenis, A., Piessen, G., Gani, C., Bruns, C.J., Moehler, M., Liakakos, T., Reynolds, J., Morganti, A., Rosati, R., Castoro, C., D'Ugo, D., Roviello, F., Bencivenga, M., Manzoni, G. de, Jeene, P., Sandick, J.W. van, Muijs, C., Slingerland, M., Nieuwenhuijzen, G., Wijnhoven, B., Beerepoot, L.V., Kolodziejczyk, P., Polkowski, W.P., Alsina, M., Pera, M., Kanonnikoff, T.F., Nilsson, M., Guckenberger, M., Monig, S., Wagner, D., Wyrwicz, L., Berbee, M., Gockel, I., Lordick, F., Griffiths, E.A., Rütten, H., Rosman, C., Verheij, M., Rossum, P.S.N. van, Laarhoven, H.W. van, Kroese, T.E., Hillegersberg, R. van, Schoppmann, S., Deseyne, P., Nafteux, P., Obermannova, R., Nordsmark, M., Pfeiffer, P., Hawkins, M.A., Smyth, E., Markar, S., Hanna, G.B., Cheong, E., Chaudry, A., Elme, A., Adenis, A., Piessen, G., Gani, C., Bruns, C.J., Moehler, M., Liakakos, T., Reynolds, J., Morganti, A., Rosati, R., Castoro, C., D'Ugo, D., Roviello, F., Bencivenga, M., Manzoni, G. de, Jeene, P., Sandick, J.W. van, Muijs, C., Slingerland, M., Nieuwenhuijzen, G., Wijnhoven, B., Beerepoot, L.V., Kolodziejczyk, P., Polkowski, W.P., Alsina, M., Pera, M., Kanonnikoff, T.F., Nilsson, M., Guckenberger, M., Monig, S., Wagner, D., Wyrwicz, L., Berbee, M., Gockel, I., Lordick, F., Griffiths, E.A., Rütten, H., Rosman, C., Verheij, M., Rossum, P.S.N. van, and Laarhoven, H.W. van

Abstract

Item does not contain fulltext, BACKGROUND: Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking. OBJECTIVE: To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in Europe. MATERIAL AND METHODS: European expert centers (n = 49) were requested to discuss 15 real-life cases in their MDT with at least a medical, surgical, and radiation oncologist present. The cases varied in terms of location and number of metastases, histology, timing of detection (i.e. synchronous versus metachronous), primary tumour treatment status, and response to systemic therapy. The primary outcome was the agreement in the definition of oligometastatic disease at diagnosis and after systemic therapy. The secondary outcome was the agreement in treatment strategies. Treatment strategies for oligometastatic disease were categorised into upfront local treatment (i.e. metastasectomy or stereotactic radiotherapy), systemic therapy followed by restaging to consider local treatment or systemic therapy alone. The agreement across MDTs was scored to be either absent/poor (<50%), fair (50%-75%), or consensus (≥75%). RESULTS: A total of 47 MDTs across 16 countries fully discussed the cases (96%). Oligometastatic disease was considered in patients with 1-2 metastases in either the liver, lung, retroperitoneal lymph nodes, adrenal gland, soft tissue or bone (consensus). At follow-up, oligometastatic disease was considered after a median of 18 weeks of systemic therapy when no progression or progression in size only of the oligometastatic lesion(s) was seen (consensus). If at restaging after a median of 18 weeks of systemic therapy the number of lesions progressed, this was not considered as oligometastatic disease (fair agreement). There was no consensus on treatment strategies for oligometastatic disease. CONCLUSION: A broad consensus on definitions of oligometastatic oesophagogastric cancer was found among MDTs of oeso

Published
2022

26. Severity of oEsophageal Anastomotic Leak in patients after oesophagectomy: the SEAL score

Author

Ubels, S., Verstegen, M.H.P., Klarenbeek, B.R., Bouwense, S., Berge Henegouwen, M.I. van, Daams, F., Det, M.J. van, Griffiths, E.A., Haveman, J.W., Heisterkamp, J., Koshy, R., Nieuwenhuijzen, G., Polat, Fatih, Siersema, P.D., Singh, P., Wijnhoven, B., Hannink, G.J., Workum, F.T.W.E. van, Rosman, C., Ubels, S., Verstegen, M.H.P., Klarenbeek, B.R., Bouwense, S., Berge Henegouwen, M.I. van, Daams, F., Det, M.J. van, Griffiths, E.A., Haveman, J.W., Heisterkamp, J., Koshy, R., Nieuwenhuijzen, G., Polat, Fatih, Siersema, P.D., Singh, P., Wijnhoven, B., Hannink, G.J., Workum, F.T.W.E. van, and Rosman, C.

Abstract

Contains fulltext : 282376.pdf (Publisher’s version ) (Open Access), BACKGROUND: Anastomotic leak (AL) is a common but severe complication after oesophagectomy. It is unknown how to determine the severity of AL objectively at diagnosis. Determining leak severity may guide treatment decisions and improve future research. This study aimed to identify leak-related prognostic factors for mortality, and to develop a Severity of oEsophageal Anastomotic Leak (SEAL) score. METHODS: This international, retrospective cohort study in 71 centres worldwide included patients with AL after oesophagectomy between 2011 and 2019. The primary endpoint was 90-day mortality. Leak-related prognostic factors were identified after adjusting for confounders and were included in multivariable logistic regression to develop the SEAL score. Four classes of leak severity (mild, moderate, severe, and critical) were defined based on the risk of 90-day mortality, and the score was validated internally. RESULTS: Some 1509 patients with AL were included and the 90-day mortality rate was 11.7 per cent. Twelve leak-related prognostic factors were included in the SEAL score. The score showed good calibration and discrimination (c-index 0.77, 95 per cent c.i. 0.73 to 0.81). Higher classes of leak severity graded by the SEAL score were associated with a significant increase in duration of ICU stay, healing time, Comprehensive Complication Index score, and Esophagectomy Complications Consensus Group classification. CONCLUSION: The SEAL score grades leak severity into four classes by combining 12 leak-related predictors and can be used to the assess severity of AL after oesophagectomy.

Published
2022

27. Identifying a core symptom set triggering radiological and endoscopic investigations for suspected recurrent esophago-gastric cancer:a modified Delphi consensus process

Author

Chidambaram, S. (Swathikan), Patel, N. M. (Nikhil M.), Sounderajah, V. (Viknesh), Alfieri, R. (Rita), Bonavina, L. (Luigi), Cheong, E. (Edward), Cockbain, A. (Andy), D’Journo, X. B. (Xavier Benoit), Ferri, L. (Lorenzo), Griffiths, E. A. (Ewen A.), Grimminger, P. (Peter), Gronnier, C. (Caroline), Gutschow, C. (Christian), Hedberg, J. (Jakob), Kauppila, J. H. (Joonas H.), Lagarde, S. (Sjoerd), Low, D. (Donald), Nafteux, P. (Philippe), Nieuwenhuijzen, G. (Grard), Nilsson, M. (Magnus), Rosati, R. (Riccardo), Schroeder, W. (Wolfgang), Smithers, B. M. (B. Mark), van Berge Henegouwen, M. I. (Mark I.), van Hillegesberg, R. (Richard), Watson, D. I. (David I.), Vohra, R. (Ravinder), Maynard, N. (Nick), Markar, S. R. (Sheraz R.), Chidambaram, S. (Swathikan), Patel, N. M. (Nikhil M.), Sounderajah, V. (Viknesh), Alfieri, R. (Rita), Bonavina, L. (Luigi), Cheong, E. (Edward), Cockbain, A. (Andy), D’Journo, X. B. (Xavier Benoit), Ferri, L. (Lorenzo), Griffiths, E. A. (Ewen A.), Grimminger, P. (Peter), Gronnier, C. (Caroline), Gutschow, C. (Christian), Hedberg, J. (Jakob), Kauppila, J. H. (Joonas H.), Lagarde, S. (Sjoerd), Low, D. (Donald), Nafteux, P. (Philippe), Nieuwenhuijzen, G. (Grard), Nilsson, M. (Magnus), Rosati, R. (Riccardo), Schroeder, W. (Wolfgang), Smithers, B. M. (B. Mark), van Berge Henegouwen, M. I. (Mark I.), van Hillegesberg, R. (Richard), Watson, D. I. (David I.), Vohra, R. (Ravinder), Maynard, N. (Nick), and Markar, S. R. (Sheraz R.)

Abstract

Summary Background: There is currently a lack of evidence-based guidelines regarding surveillance for recurrence after esophageal and gastric (OG) cancer surgical resection, and which symptoms should prompt endoscopic or radiological investigations for recurrence. The aim of this study was to develop a core symptom set using a modified Delphi consensus process that should guide clinicians to carry out investigations to look for suspected recurrent OG cancer in previously asymptomatic patients. Methods: A web-based survey of 42 questions was sent to surgeons performing OG cancer resections at high volume centers. The first section evaluated the structure of follow-up and the second, determinants of follow-up. Two rounds of a modified Delphi consensus process and a further consensus workshop were used to determine symptoms warranting further investigations. Symptoms with a 75% consensus agreement as suggestive of recurrent cancer were included in the core symptom set. Results: 27 surgeons completed the questionnaires. A total of 70.3% of centers reported standardized surveillance protocols, whereas 3.7% of surgeons did not undertake any surveillance in asymptomatic patients after OG cancer resection. In asymptomatic patients, 40.1% and 25.9% of centers performed routine imaging and endoscopy, respectively. The core set that reached consensus, consisted of eight symptoms that warranted further investigations included; dysphagia to solid food, dysphagia to liquids, vomiting, abdominal pain, chest pain, regurgitation of foods, unexpected weight loss and progressive hoarseness of voice. Conclusion: There is global variation in monitoring patients after OG cancer resection. Eight symptoms were identified by the consensus process as important in prompting radiological or endoscopic investigation for suspected recurrent malignancy. Further randomized controlled trials are necessary to link surveillance strategies to survival outcomes and evaluate prognostic value.

Published
2022

28. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ('ugly') locally advanced rectal cancer:study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT)

Author

van den Berg, K., Schaap, D. P., Voogt, E. L.K., Buffart, T. E., Verheul, H. M.W., de Groot, J. W.B., Verhoef, C., Melenhorst, J., Roodhart, J. M.L., de Wilt, J. H.W., van Westreenen, H. L., Aalbers, A. G.J., van 't Veer, M., Marijnen, C. A.M., Vincent, J., Simkens, L. H.J., Peters, N. A.J.B., Berbée, M., Werter, I. M., Snaebjornsson, P., Peulen, H. M.U., van Lijnschoten, I. G., Roef, M. J., Nieuwenhuijzen, G. A.P., Bloemen, J. G., Willems, J. M.W.E., Creemers, G. J.M., Nederend, J., Rutten, H. J.T., Burger, J. W.A., van den Berg, K., Schaap, D. P., Voogt, E. L.K., Buffart, T. E., Verheul, H. M.W., de Groot, J. W.B., Verhoef, C., Melenhorst, J., Roodhart, J. M.L., de Wilt, J. H.W., van Westreenen, H. L., Aalbers, A. G.J., van 't Veer, M., Marijnen, C. A.M., Vincent, J., Simkens, L. H.J., Peters, N. A.J.B., Berbée, M., Werter, I. M., Snaebjornsson, P., Peulen, H. M.U., van Lijnschoten, I. G., Roef, M. J., Nieuwenhuijzen, G. A.P., Bloemen, J. G., Willems, J. M.W.E., Creemers, G. J.M., Nederend, J., Rutten, H. J.T., and Burger, J. W.A.

Abstract

BACKGROUND: The presence of mesorectal fascia (MRF) invasion, grade 4 extramural venous invasion (EMVI), tumour deposits (TD) or extensive or bilateral extramesorectal (lateral) lymph nodes (LLN) on MRI has been suggested to identify patients with indisputable, extensive locally advanced rectal cancer (LARC), at high risk of treatment failure. The aim of this study is to evaluate whether or not intensified chemotherapy prior to neoadjuvant chemoradiotherapy improves the complete response (CR) rate in these patients. METHODS: This multicentre, single-arm, open-label, phase II trial will include 128 patients with non-metastatic high-risk LARC (hr-LARC), fit for triplet chemotherapy. To ensure a study population with indisputable, unfavourable prognostic characteristics, hr-LARC is defined as LARC with on baseline MRI at least one of the following characteristics; MRF invasion, EMVI grade 4, enlarged bilateral or extensive LLN at high risk of an incomplete resection, or TD. Exclusion criteria are the presence of a homozygous DPD deficiency, distant metastases, any chemotherapy within the past 6 months, previous radiotherapy within the pelvic area precluding standard chemoradiotherapy, and any contraindication for the planned treatment. All patients will be planned for six two-weekly cycles of FOLFOXIRI (5-fluorouracil, leucovorin, oxaliplatin and irinotecan) prior to chemoradiotherapy (25 × 2 Gy or 28 × 1.8 Gy with concomitant capecitabine). A resection will be performed following radiological confirmation of resectable disease after the completion of chemoradiotherapy. A watch and wait strategy is allowed in case of a clinical complete response. The primary endpoint is the CR rate, described as a pathological CR or a sustained clinical CR one year after chemoradiotherapy. The main secondary objectives are long-term oncological outcomes, radiological and pathological response, the number of resections with clear margins, treatment-related toxicity, perioperative com

Published
2022

29. Outcomes on diverting ostomy formation and reversal after low anterior resection in the older more advanced rectal cancer patient

Author

Ketelaers, S H J, Orsini, R G, Nieuwenhuijzen, G A P, Rutten, H J T, Burger, J W A, Bloemen, J G, Ketelaers, S H J, Orsini, R G, Nieuwenhuijzen, G A P, Rutten, H J T, Burger, J W A, and Bloemen, J G

Abstract

BACKGROUND: To decrease morbidity caused by anastomotic leakages after a low anterior resection (LAR) with primary anastomosis, a diverting ostomy is often created. Reversal of a diverting ostomy is associated with morbidity, which may result in non-reversal, particularly in the elderly. This study aimed to describe the diverting ostomy-related outcomes in elderly patients with more advanced rectal cancer after LAR.MATERIALS AND METHODS: All rectosigmoid and rectal cancer patients ≥70 years who underwent LAR with primary anastomosis between 2006 and 2019 in the Catharina Hospital (Eindhoven, The Netherlands) were included for analyses. Reversal rates, ostomy-related complications, morbidity and mortality after ostomy reversal, and definitive ostomy rates were evaluated.RESULTS: In total 164 patients were included, of which 150 (91.5%) underwent primary or secondary ostomy creation. Ostomy-related complications were reported in 34.7% (95%-CI 27.1-42.9%). In total, 72.5% (95%-CI 64.2-79.7%) reversed their diverting ostomy. Non-reversal was mostly due to relapsing disease (52.6%). Median time to ostomy reversal was 3.2 months (IQR 2.3-5.0). No or minor complications after ostomy reversal were observed in 84.0% (95%-CI 75.3-90.6%). Over time, ostomy recreation was performed in 15.0% (95%-CI 8.6-23.5%), and ultimately 65.8% (95%-CI 57.8-73.2%) were ostomy-free after the median follow-up of 3.8 years.CONCLUSION: Although most elderly successfully reversed their diverting ostomy after LAR with limited morbidity, attention should be paid for the risk of non-reversal and ostomy recreation over time. Preoperative patient counselling is important in every individual to be able to decide if LAR with primary anastomosis or a permanent end colostomy is preferred.

Published
2022

30. Clinical variation in the organization of clinical pathways in esophagogastric cancer, a mixed method multiple case study

Author

MS Medische Oncologie, Cancer, Luijten, J C H B M, Vissers, P A J, Brom, L, de Bièvre, M, Buijsen, J, Rozema, T, Mohammad, N Haj, van Duijvendijk, P, Kouwenhoven, E A, Eshuis, W J, Rosman, C, Siersema, P D, van Laarhoven, H W M, Verhoeven, R H A, Nieuwenhuijzen, G A P, Westerman, M J, MS Medische Oncologie, Cancer, Luijten, J C H B M, Vissers, P A J, Brom, L, de Bièvre, M, Buijsen, J, Rozema, T, Mohammad, N Haj, van Duijvendijk, P, Kouwenhoven, E A, Eshuis, W J, Rosman, C, Siersema, P D, van Laarhoven, H W M, Verhoeven, R H A, Nieuwenhuijzen, G A P, and Westerman, M J

Published
2022

31. Team dynamics and clinician's experience influence decision-making during Upper-GI multidisciplinary team meetings: A multiple case study

Author

MS CGO, Cancer, Luijten, J C H B M, Westerman, M J, Nieuwenhuijzen, G A P, Walraven, J E W, Sosef, M N, Beerepoot, L V, van Hillegersberg, R, Muller, K, Hoekstra, R, Bergman, J J G H M, Siersema, P D, van Laarhoven, H W M, Rosman, C, Brom, L, Vissers, P A J, Verhoeven, R H A, MS CGO, Cancer, Luijten, J C H B M, Westerman, M J, Nieuwenhuijzen, G A P, Walraven, J E W, Sosef, M N, Beerepoot, L V, van Hillegersberg, R, Muller, K, Hoekstra, R, Bergman, J J G H M, Siersema, P D, van Laarhoven, H W M, Rosman, C, Brom, L, Vissers, P A J, and Verhoeven, R H A

Published
2022

32. Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk (“ugly”) locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT)

Author

MS Medische Oncologie, Cancer, van den Berg, K., Schaap, D. P., Voogt, E. L.K., Buffart, T. E., Verheul, H. M.W., de Groot, J. W.B., Verhoef, C., Melenhorst, J., Roodhart, J. M.L., de Wilt, J. H.W., van Westreenen, H. L., Aalbers, A. G.J., van ‘t Veer, M., Marijnen, C. A.M., Vincent, J., Simkens, L. H.J., Peters, N. A.J.B., Berbée, M., Werter, I. M., Snaebjornsson, P., Peulen, H. M.U., van Lijnschoten, I. G., Roef, M. J., Nieuwenhuijzen, G. A.P., Bloemen, J. G., Willems, J. M.W.E., Creemers, G. J.M., Nederend, J., Rutten, H. J.T., Burger, J. W.A., MS Medische Oncologie, Cancer, van den Berg, K., Schaap, D. P., Voogt, E. L.K., Buffart, T. E., Verheul, H. M.W., de Groot, J. W.B., Verhoef, C., Melenhorst, J., Roodhart, J. M.L., de Wilt, J. H.W., van Westreenen, H. L., Aalbers, A. G.J., van ‘t Veer, M., Marijnen, C. A.M., Vincent, J., Simkens, L. H.J., Peters, N. A.J.B., Berbée, M., Werter, I. M., Snaebjornsson, P., Peulen, H. M.U., van Lijnschoten, I. G., Roef, M. J., Nieuwenhuijzen, G. A.P., Bloemen, J. G., Willems, J. M.W.E., Creemers, G. J.M., Nederend, J., Rutten, H. J.T., and Burger, J. W.A.

Published
2022

33. Impact of nationwide centralization of oesophageal, gastric, and pancreatic surgery on travel distance and experienced burden in the Netherlands

Author

Arts Assistenten CTC, MS CGO, Cancer, MS HOD, Luijten, J. C.H.B.M., Nieuwenhuijzen, G. A.P., Sosef, M. N., de Hingh, I. H.J.T., Rosman, C., Ruurda, J. P., van Duijvendijk, P., Heisterkamp, J., de Steur, W. O., van Laarhoven, H. W.M., Besselink, M. G., Groot Koerkamp, B., van Santvoort, H. C., Lemmens, V. E.P., Vissers, P. A.J., Arts Assistenten CTC, MS CGO, Cancer, MS HOD, Luijten, J. C.H.B.M., Nieuwenhuijzen, G. A.P., Sosef, M. N., de Hingh, I. H.J.T., Rosman, C., Ruurda, J. P., van Duijvendijk, P., Heisterkamp, J., de Steur, W. O., van Laarhoven, H. W.M., Besselink, M. G., Groot Koerkamp, B., van Santvoort, H. C., Lemmens, V. E.P., and Vissers, P. A.J.

Published
2022

37. 10: INTRATHORACIC VERSUS CERVICAL ANASTOMOSIS AFTER MINIMALLY INVASIVE OESOPHAGECTOMY FOR OESOPHAGEAL CANCER: A RANDOMISED CONTROLLED TRIAL

Author

Van Workum, F, primary, Verstegen, M, additional, Klarenbeek, B, additional, Bouwense, S, additional, Van Berge Henegouwen, M, additional, Daams, F, additional, Gisbertz, S, additional, Hannink, G, additional, Haveman, J W, additional, Heisterkamp, J, additional, Jansen, W, additional, Kouwenhoven, E, additional, Van Lanschot, J, additional, Nieuwenhuijzen, G, additional, Van Der Peet, D, additional, Polat, F, additional, Ubels, S, additional, Wijnhoven, B, additional, Rovers, M, additional, and Rosman, C, additional

Published
2022
Full Text
View/download PDF

38. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe

Author

Kroese, T.E. van Hillegersberg, R. Schoppmann, S. Deseyne, P.R.A.J. Nafteux, P. Obermannova, R. Nordsmark, M. Pfeiffer, P. Hawkings, M.A. Smyth, E. Markar, S. Hanna, G.B. Cheong, E. Chaudry, A. Elme, A. Adenis, A. Piessen, G. Gani, C. Bruns, C.J. Moehler, M. Liakakos, T. Reynolds, J. Morganti, A. Rosati, R. Castoro, C. D'Ugo, D. Roviello, F. Bencivenga, M. de Manzoni, G. Jeene, P. van Sandick, J.W. Muijs, C. Slingerland, M. Nieuwenhuijzen, G. Wijnhoven, B. Beerepoot, L.V. Kolodziejczyk, P. Polkowski, W.P. Alsina, M. Pera, M. Kanonnikoff, T.F. Nilsson, M. Guckenberger, M. Monig, S. Wagner, D. Wyrwicz, L. Berbee, M. Gockel, I. Lordick, F. Griffiths, E.A. Verheij, M. van Rossum, P.S.N. van Laarhoven, H.W.M. Rosman, C. Rütten, H. Gootjes, E.C. Vonken, F.E.M. van Dieren, J.M. Vollebergh, M.A. van der Sangen, M. Creemers, G.-J. Zander, T. Schlößer, H. Cascinu, S. Mazza, E. Nicoletti, R. Damascelli, A. Slim, N. Passoni, P. Cossu, A. Puccetti, F. Barbieri, L. Fanti, L. Azzolini, F. Ventoruzzo, F. Szczepanik, A. Visa, L. Reig, A. Roques, T. Harrison, M. Ciseł, B. Pikuła, A. Skórzewska, M. Vanommeslaeghe, H. Van Daele, E. Pattyn, P. Geboes, K. Callebout, E. Ribeiro, S. van Duijvendijk, P. Tromp, C. Sosef, M. Warmerdam, F. Heisterkamp, J. Vera, A. Jordá, E. López-Mozos, F. Fernandez-Moreno, M.C. Barrios-Carvajal, M. Huerta, M. de Steur, W. Lips, I. Diez, M. Castro, S. O'Neill, R. Holyoake, D. Hacker, U. Denecke, T. Kuhnt, T. Hoffmeister, A. Kluge, R. Bostel, T. Grimminger, P. Jedlička, V. Křístek, J. Pospíšil, P. Mourregot, A. Maurin, C. Starling, N. Chong, I. OMEC working group

Abstract

Background: Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking. Objective: To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in Europe. Material and methods: European expert centers (n = 49) were requested to discuss 15 real-life cases in their MDT with at least a medical, surgical, and radiation oncologist present. The cases varied in terms of location and number of metastases, histology, timing of detection (i.e. synchronous versus metachronous), primary tumour treatment status, and response to systemic therapy. The primary outcome was the agreement in the definition of oligometastatic disease at diagnosis and after systemic therapy. The secondary outcome was the agreement in treatment strategies. Treatment strategies for oligometastatic disease were categorised into upfront local treatment (i.e. metastasectomy or stereotactic radiotherapy), systemic therapy followed by restaging to consider local treatment or systemic therapy alone. The agreement across MDTs was scored to be either absent/poor (

Published
2022

39. Additional file 1 of Clinical variation in the organization of clinical pathways in esophagogastric cancer, a mixed method multiple case study

Author

Luijten, J. C. H. B. M., Vissers, P. A. J., Brom, L., de Bièvre, M., Buijsen, J., Rozema, T., Mohammad, N. Haj, van Duijvendijk, P., Kouwenhoven, E. A., Eshuis, W. J., Rosman, C., Siersema, P. D., van Laarhoven, H. W. M., Verhoeven, R. H. A., Nieuwenhuijzen, G. A. P., and Westerman, M. J.

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2022
Full Text
View/download PDF

42. Perioperative management and anaesthetic considerations in pelvic exenterations using Delphi methodology: results from the PelvEx Collaborative

Author

PelvEx Collaborative, [missing], Chok, A Y, Oliver, A, Rasheed, S, Tan, E J, Kelly, M E, Aalbers, A G J, Abdul Aziz, N, Abecasis, N, Abraham-Nordling, M, Akiyoshi, T, Alberda, W, Albert, M, Andric, M, Angenete, E, Antoniou, A, Auer, R, Austin, K K, Aziz, O, Baker, R P, Bali, M, Baseckas, G, Bebington, B, Bedford, M, Bednarski, B K, Beets, G L, Berg, P L, Beynon, J, Biondo, S, Boyle, K, Bordeianou, L, Bremers, A B, Brunner, M, Buchwald, P, Bui, A, Burgess, A, Burger, J W A, Burling, D, Burns, E, Campain, N, Carvalhal, S, Castro, L, Caycedo-Marulanda, A, Chan, K K L, Chang, G J, Chew, M H, Chong, P, Christensen, H K, Clouston, H, Codd, M, Collins, D, Colquhoun, A J, Corr, A, Coscia, M, Coyne, P E, Creavin, B, Croner, R S, Damjanovic, L, Daniels, I R, Davies, M, Davies, R J, Delaney, C P, de Wilt, J H W, Denost, Q, Deutsch, C, Dietz, D, Domingo, S, Dozois, E J, Duff, M, Eglinton, T, Enrique-Navascues, J M, Espin-Basany, E, Evans, M D, Fearnhead, N S, Flatmark, K, Fleming, F, Frizelle, F A, Gallego, M A, Garcia-Granero, E, Garcia-Sabrido, J L, Gentilini, L, George, M L, George, V, Ghouti, L, Giner, F, Ginther, N, Glynn, R, Golda, T, Griffiths, B, Harris, D A, Hagemans, J A W, Hanchanale, V, Harji, D P, Helewa, R M, Hellawell, G, Heriot, A G, Hochman, D, Hohenberger, W, Holm, T, Holmström, A, Hompes, R, Jenkins, J T, Kaffenberger, S, Kandaswamy, G V, Kapur, S, Kanemitsu, Y, Kelley, S R, Keller, D S, Khan, M S, Kim, H, Kim, H J, Koh, C E, Kok, N F M, Kokelaar, R, Kontovounisios, C, Kristensen, H Ø, Kroon, H M, Kusters, M, Lago, V, Larsen, S G, Larson, D W, Law, W L, Laurberg, S, Lee, P J, Limbert, M, Lydrup, M L, Lyons, A, Lynch, A C, Mantyh, C, Mathis, K L, Margues, C F S, Martling, A, Meijerink, W J H J, Merkel, S, Mehta, A M, McArthur, D R, McDermott, F D, McGrath, J S, Malde, S, Mirnezami, A, Monson, J R T, Morton, J R, Mullaney, T G, Negoi, I, Neto, J W M, Nguyen, B, Nielsen, M B, Nieuwenhuijzen, G A P, Nilsson, P J, O’Dwyer, S T, Palmer, G, Pappou, E, Park, J, Patsouras, D, Pellino, G, Peterson, A C, Poggioli, G, Proud, D, Quinn, M, Quyn, A, Radwan, R W, Rasmussen, P C, Rausa, E, Regenbogen, S E, Renehan, A, Rocha, R, Rochester, M, Rohila, J, Rothbarth, J, Rottoli, M, Roxburgh, C, Rutten, H J T, Ryan, É J, Safar, B, Sagar, P M, Sahai, A, Saklani, A, Sammour, T, Sayyed, R, Schizas, A M P, Schwarzkopf, E, Scripcariu, V, Selvasekar, C, Shaikh, I, Shida, D, Simpson, A, Smart, N J, Smart, P, Smith, J J, Solbakken, A M, Solomon, M J, Sørensen, M M, Steele, S R, Steffens, D, Stitzenberg, K, Stocchi, L, Stylianides, N A, Swartling, T, Sumrien, H, Sutton, P A, Swartking, T, Taylor, C, Teras, J, Thurairaja, R, Toh, E L, Tsarkov, P, Tsukada, Y, Tsukamoto, S, Tuech, J J, Turner, W H, Tuynman, J B, van Ramshorst, Gabriëlle, Zoggel, D van, Vasquez-Jimenez, W, Verhoef, C, Vizzielli, G, Voogt, E L K, Uehara, K, Wakeman, C, Warrier, S, Wasmuth, H H, Weber, K, Weiser, M R, Wheeler, J M D, Wild, J, Wilson, M, Wolthuis, A, Yano, H, Yip, B, Yip, J, Yoo, R N, Winter, D C, Tekkis, P P, Surgery, Chok, A Y, Oliver, A, Rasheed, S, Tan, E J, Kelly, M E, Aalbers, A G J, Abdul Aziz, N, Abecasis, N, Abraham-Nordling, M, Akiyoshi, T, Alberda, W, Albert, M, Andric, M, Angenete, E, Antoniou, A, Auer, R, Austin, K K, Aziz, O, Baker, R P, Bali, M, Baseckas, G, Bebington, B, Bedford, M, Bednarski, B K, Beets, G L, Berg, P L, Beynon, J, Biondo, S, Boyle, K, Bordeianou, L, Bremers, A B, Brunner, M, Buchwald, P, Bui, A, Burgess, A, Burger, J W A, Burling, D, Burns, E, Campain, N, Carvalhal, S, Castro, L, Caycedo-Marulanda, A, Chan, K K L, Chang, G J, Chew, M H, Chong, P, Christensen, H K, Clouston, H, Codd, M, Collins, D, Colquhoun, A J, Corr, A, Coscia, M, Coyne, P E, Creavin, B, Croner, R S, Damjanovic, L, Daniels, I R, Davies, M, Davies, R J, Delaney, C P, de Wilt, J H W, Denost, Q, Deutsch, C, Dietz, D, Domingo, S, Dozois, E J, Duff, M, Eglinton, T, Enrique-Navascues, J M, Espin-Basany, E, Evans, M D, Fearnhead, N S, Flatmark, K, Fleming, F, Frizelle, F A, Gallego, M A, Garcia-Granero, E, Garcia-Sabrido, J L, Gentilini, L, George, M L, George, V, Ghouti, L, Giner, F, Ginther, N, Glynn, R, Golda, T, Griffiths, B, Harris, D A, Hagemans, J A W, Hanchanale, V, Harji, D P, Helewa, R M, Hellawell, G, Heriot, A G, Hochman, D, Hohenberger, W, Holm, T, Holmström, A, Hompes, R, Jenkins, J T, Kaffenberger, S, Kandaswamy, G V, Kapur, S, Kanemitsu, Y, Kelley, S R, Keller, D S, Khan, M S, Kim, H, Kim, H J, Koh, C E, Kok, N F M, Kokelaar, R, Kontovounisios, C, Kristensen, H Ø, Kroon, H M, Kusters, M, Lago, V, Larsen, S G, Larson, D W, Law, W L, Laurberg, S, Lee, P J, Limbert, M, Lydrup, M L, Lyons, A, Lynch, A C, Mantyh, C, Mathis, K L, Margues, C F S, Martling, A, Meijerink, W J H J, Merkel, S, Mehta, A M, McArthur, D R, McDermott, F D, McGrath, J S, Malde, S, Mirnezami, A, Monson, J R T, Morton, J R, Mullaney, T G, Negoi, I, Neto, J W M, Nguyen, B, Nielsen, M B, Nieuwenhuijzen, G A P, Nilsson, P J, O’Dwyer, S T, Palmer, G, Pappou, E, Park, J, Patsouras, D, Pellino, G, Peterson, A C, Poggioli, G, Proud, D, Quinn, M, Quyn, A, Radwan, R W, Rasmussen, P C, Rausa, E, Regenbogen, S E, Renehan, A, Rocha, R, Rochester, M, Rohila, J, Rothbarth, J, Rottoli, M, Roxburgh, C, Rutten, H J T, Ryan, É J, Safar, B, Sagar, P M, Sahai, A, Saklani, A, Sammour, T, Sayyed, R, Schizas, A M P, Schwarzkopf, E, Scripcariu, V, Selvasekar, C, Shaikh, I, Shida, D, Simpson, A, Smart, N J, Smart, P, Smith, J J, Solbakken, A M, Solomon, M J, Sørensen, M M, Steele, S R, Steffens, D, Stitzenberg, K, Stocchi, L, Stylianides, N A, Swartling, T, Sumrien, H, Sutton, P A, Swartking, T, Taylor, C, Teras, J, Thurairaja, R, Toh, E L, Tsarkov, P, Tsukada, Y, Tsukamoto, S, Tuech, J J, Turner, W H, Tuynman, J B, Ramshorst, G H van, Zoggel, D van, Vasquez-Jimenez, W, Verhoef, C, Vizzielli, G, Voogt, E L K, Uehara, K, Wakeman, C, Warrier, S, Wasmuth, H H, Weber, K, Weiser, M R, Wheeler, J M D, Wild, J, Wilson, M, Wolthuis, A, Yano, H, Yip, B, Yip, J, Yoo, R N, Winter, D C, Tekkis, P P, Mcarthur, D R, Mcdermott, F D, Mcgrath, J S, Psychiatrie & Neuropsychologie, RS: MHeNs - R1 - Cognitive Neuropsychiatry and Clinical Neuroscience, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Faculteit FHML Centraal, Health Services Research, RS: CAPHRI - R1 - Ageing and Long-Term Care, RS: FdR IC Goederenrecht, School Office GROW, and Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
BLOOD-TRANSFUSION, CARDIAC RISK, AcademicSubjects/MED00910, medicine.medical_treatment, Delphi method, Computer-assisted web interviewing, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 0302 clinical medicine, 030202 anesthesiology, Multidisciplinary approach, Medicine and Health Sciences, Medicine, humans, RISK, COMPLICATIONS, Perioperative management - anaesthetic - pelvic exenterations - rectal cancer - Delphi - PelvEx Collaborative, Manchester Cancer Research Centre, General Medicine, SYSTEMIC INFLAMMATORY RESPONSE, 030220 oncology & carcinogenesis, Original Article, Medical emergency, EPIDURAL-ANESTHESIA, AcademicSubjects/MED00010, Life Sciences & Biomedicine, Consensus, ENHANCED RECOVERY, Best practice, education, MEDLINE, patient care team/organization & administration, 03 medical and health sciences, anesthetics, Humans, MAJOR ABDOMINAL-SURGERY, METAANALYSIS, RECTAL-CANCER, Anesthetics, Patient Care Team, Science & Technology, Pelvic exenteration, business.industry, ResearchInstitutes_Networks_Beacons/mcrc, MORTALITY, LONG-TERM SURVIVAL, Perioperative, COMPARTMENT SYNDROME, medicine.disease, pelvic exenteration, Pelvic Exenteration, Subject-matter expert, consensus, Surgery, business
Abstract

Background The multidisciplinary perioperative and anaesthetic management of patients undergoing pelvic exenteration is essential for good surgical outcomes. No clear guidelines have been established, and there is wide variation in clinical practice internationally. This consensus statement consolidates clinical experience and best practice collectively, and systematically addresses key domains in the perioperative and anaesthetic management. Methods The modified Delphi methodology was used to achieve consensus from the PelvEx Collaborative. The process included one round of online questionnaire involving controlled feedback and structured participant response, two rounds of editing, and one round of web-based voting. It was held from December 2019 to February 2020. Consensus was defined as more than 80 per cent agreement, whereas less than 80 per cent agreement indicated low consensus. Results The final consensus document contained 47 voted statements, across six key domains of perioperative and anaesthetic management in pelvic exenteration, comprising preoperative assessment and preparation, anaesthetic considerations, perioperative management, anticipating possible massive haemorrhage, stress response and postoperative critical care, and pain management. Consensus recommendations were developed, based on consensus agreement achieved on 34 statements. Conclusion The perioperative and anaesthetic management of patients undergoing pelvic exenteration is best accomplished by a dedicated multidisciplinary team with relevant domain expertise in the setting of a specialized tertiary unit. This consensus statement has addressed key domains within the framework of current perioperative and anaesthetic management among patients undergoing pelvic exenteration, with an international perspective, to guide clinical practice, and has outlined areas for future clinical research., The PelvEx Collaborative consensus statement systematically addresses the perioperative and anaesthetic management of patients undergoing pelvic exenteration (PE). Using the modified Delphi methodology, recommendations across six key clinical domains comprising preoperative assessment and preparation, anaesthetic considerations, perioperative management, anticipating possible massive haemorrhage, stress response and postoperative critical care, and pain management were developed. pelvic exenteratio and recommendation

Published
2021

44. Prospective nationwide outcome audit of surgery for suspected acute appendicitis

Author

van Rossem, C. C., Bolmers, M. D. M., Schreinemacher, M. H. F., van Geloven, A. A. W., Bemelman, W. A., van Acker, G. J. D., Akkermans, B., Akkersdijk, G. J. M., Algie, G. D., Allema, J. H., Andeweg, C. S., Appeldorn, N., van Baal, J. G., den Bakker, C. M., Bartels, S. A. L., van den Berg, C., Boekestijn, B., den Boer, F. C., Boerma, D., van den Boom, A. L., Boute, M. C., Bouwense, S. A. W., Bransen, J., van Brussel, F. A., Busch, O. R. C., de Castro, S. M. M., Cense, H. A., Croese, C., van Dalen, T., Dawson, I., van Dessel, E., Dettmers, R., Dhar, N., Dohmen, F. Y. M., van Dongen, K. W., van Duijvendijk, P., Dulfer, R. R., Dwars, B. J., Eerenberg, J. P., van der Elst, M., van den Ende, E., Fassaert, L. M. M., Fikkers, J. T., Foppen, J. W., Furnee, E. J. B., Garssen, F. P., Gerhards, M. F., van Goor, H., Gorter, R. R., de Graaf, J. S., Graat, L. J., Groote, J., van der Ham, A. C., Hamming, J. F., Hamminga, J. T. H., van der Harst, E., Heemskerk, J., Heij, H. A., Heijne, A., Heikens, J. T., Heineman, E., Hertogs, R., van Heurn, E., van den Hil, L. C. L., Hoofwijk, A. G. M., Hulsker, C. C. C., Hunen, D. R. M., Ibelings, M. S., Klaase, J. M., Klicks, R., Knaapen, L., Kortekaas, R. T. J., Kruyt, F., Kwant, S., Lases, S. S., Lettinga, T., Loupatty, A., Matthijsen, R. A., Minnee, R. C., Mirck, B., Mitalas, L., Moes, D., Moorman, A. M., Nieuwenhuijs, V. B., Nieuwenhuijzen, G. A. P., Nijk, P. D., Omloo, J. M. T., Ottenhof, A. G., Palamba, H. W., van der Peet, D. L., Pereboom, I. T. A., Plaisier, P. W., van der Ploeg, A. P. T., Raber, M. H., Reijnen, M. M. P. J., Rijna, H., Rosman, C., Roumen, R. M. H., Schmitz, R. F., van der Velden, Schouten A. P., Schreurs, W. H., Sigterman, T. A., Smeets, H. J., Sonneveld, D. J. A., Sosef, M. N., Spoor, S. F., Stassen, L. P. S., van Steensel, L., Stortelder, E., Straatman, J., van Susante, H. J., de Hoog, Suykerbuyk D. E. N. M., van Scheltinga, Terwisscha C., Toorenvliet, B. R., Verbeek, B. M., Verbeek, P. C. M., Verseveld, M., Volders, J. H., Vriens, M. R., Vriens, P. W. H. E., Vrouenraets, B. C., van de Wall, B. J. M., Wegdam, J. A., Westerduin, E., Wever, J. J., Wijffels, N. A. T., Wijnhoven, B. P. L., Winkel, T. A., van der Zee, D. C., Zeillemaker, A. M., and Zietse, C.

Published
2016
Full Text
View/download PDF

45. Predicting outcomes of pelvic exenteration using machine learning

Author

Dudurych I., Kelly M. E., Aalbers A. G. J., Abdul Aziz N., Abecasis N., Abraham-Nordling M., Akiyoshi T., Alberda W., Albert M., Andric M., Angenete E., Antoniou A., Auer R., Austin K. K., Aziz O., Baker R. P., Bali M., Baseckas G., Bebington B., Bedford M., Bednarski B. K., Beets G. L., Berg P. L., Beynon J., Biondo S., Boyle K., Bordeianou L., Bremers A. B., Brunner M., Buchwald P., Bui A., Burgess A., Burger J. W. A., Burling D., Burns E., Campain N., Carvalhal S., Castro L., Caycedo-Marulanda A., Chan K. K. L., Chang G. J., Chew M. H., Chok A. K., Chong P., Christensen H. K., Clouston H., Codd M., Collins D., Colquhoun A. J., Corr A., Coscia M., Coyne P. E., Creavin B., Croner R. S., Damjanovic L., Daniels I. R., Davies M., Davies R. J., Delaney C. P., Wilt J. H. W., Denost Q., Deutsch C., Dietz D., Domingo S., Dozois E. J., Duff M., Eglinton T., Enrique-Navascues J. M., Espin-Basany E., Evans M. D., Fearnhead N. S., Flatmark K., Fleming F., Frizelle F. A., Gallego M. A., Garcia-Granero E., Garcia-Sabrido J. L., Gentilini L., George M. L., George V., Ghouti L., Giner F., Ginther N., Glynn R., Golda T., Griffiths B., Harris D. A., Hagemans J. A. W., Hanchanale V., Harji D. P., Helewa R. M., Heriot A. G., Hochman D., Hohenberger W., Holm T., Hompes R., Jenkins J. T., Kaffenberger S., Kandaswamy G. V., Kapur S., Kanemitsu Y., Kelley S. R., Keller D. S., Khan M. S., Kiran R. P., Kim H., Kim H. J., Koh C. E., Kok N. F. M., Kokelaar R., Kontovounisios C., Kristensen H. O., Kroon H. M., Kusters M., Lago V., Larsen S. G., Larson D. W., Law W. L., Laurberg S., Lee P. J., Limbert M., Lydrup M. L., Lyons A., Lynch A. C., Mantyh C., Mathis K. L., Margues C. F. S., Martling A., Meijerink W. J. H. J., Merkel S., Mehta A. M., McArthur D. R., McDermott F. D., McGrath J. S., Malde S., Mirnezami A., Monson J. R. T., Morton J. R., Mullaney T. G., Negoi I., Neto J. W. M., Nguyen B., Nielsen M. B., Nieuwenhuijzen G. A. P., Nilsson P. J., Oliver A., O'Connell P. R., O'Dwyer S. T., Palmer G., Pappou E., Park J., Patsouras D., Pellino G., Peterson A. C., Poggioli G., Proud D., Quinn M., Quyn A., Radwan R. W., Rasheed S., Rasmussen P. C., Regenbogen S. E., Renehan A., Rocha R., Rochester M., Rohila J., Rothbarth J., Rottoli M., Roxburgh C., Rutten H. J. T., Ryan E. J., Safar B., Sagar P. M., Sahai A., Saklani A., Sammour T., Sayyed R., Schizas A. M. P., Schwarzkopf E., Scripcariu V., Selvasekar C., Shaikh I., Shellawell G., Shida D., Simpson A., Smart N. J., Smart P., Smith J. J., Solbakken A. M., Solomon M. J., Sorensen M. M., Steele S. R., Steffens D., Stitzenberg K., Stocchi L., Stylianides N. A., Swartling T., Sumrien H., Sutton P. A., Swartking T., Tan E. J., Taylor C., Tekkis P. P., Teras J., Thurairaja R., Toh E. L., Tsarkov P., Tsukada Y., Tsukamoto S., Tuech J. J., Turner W. H., Tuynman J. B., van Ramshorst G. H., van Zoggel D., Vasquez-Jimenez W., Verhoef C., Vizzielli G., Voogt E. L. K., Uehara K., Wakeman C., Warrier S., Wasmuth H. H., Weber K., Weiser M. R., Wheeler J. M. D., Wild J., Wilson M., Wolthuis A., Yano H., Yip B., Yip J., Yoo R. N., Winter D. C., Dudurych I., Kelly M.E., Aalbers A.G.J., Abdul Aziz N., Abecasis N., Abraham-Nordling M., Akiyoshi T., Alberda W., Albert M., Andric M., Angenete E., Antoniou A., Auer R., Austin K.K., Aziz O., Baker R.P., Bali M., Baseckas G., Bebington B., Bedford M., Bednarski B.K., Beets G.L., Berg P.L., Beynon J., Biondo S., Boyle K., Bordeianou L., Bremers A.B., Brunner M., Buchwald P., Bui A., Burgess A., Burger J.W.A., Burling D., Burns E., Campain N., Carvalhal S., Castro L., Caycedo-Marulanda A., Chan K.K.L., Chang G.J., Chew M.H., Chok A.K., Chong P., Christensen H.K., Clouston H., Codd M., Collins D., Colquhoun A.J., Corr A., Coscia M., Coyne P.E., Creavin B., Croner R.S., Damjanovic L., Daniels I.R., Davies M., Davies R.J., Delaney C.P., Wilt J.H.W., Denost Q., Deutsch C., Dietz D., Domingo S., Dozois E.J., Duff M., Eglinton T., Enrique-Navascues J.M., Espin-Basany E., Evans M.D., Fearnhead N.S., Flatmark K., Fleming F., Frizelle F.A., Gallego M.A., Garcia-Granero E., Garcia-Sabrido J.L., Gentilini L., George M.L., George V., Ghouti L., Giner F., Ginther N., Glynn R., Golda T., Griffiths B., Harris D.A., Hagemans J.A.W., Hanchanale V., Harji D.P., Helewa R.M., Heriot A.G., Hochman D., Hohenberger W., Holm T., Hompes R., Jenkins J.T., Kaffenberger S., Kandaswamy G.V., Kapur S., Kanemitsu Y., Kelley S.R., Keller D.S., Khan M.S., Kiran R.P., Kim H., Kim H.J., Koh C.E., Kok N.F.M., Kokelaar R., Kontovounisios C., Kristensen H.O., Kroon H.M., Kusters M., Lago V., Larsen S.G., Larson D.W., Law W.L., Laurberg S., Lee P.J., Limbert M., Lydrup M.L., Lyons A., Lynch A.C., Mantyh C., Mathis K.L., Margues C.F.S., Martling A., Meijerink W.J.H.J., Merkel S., Mehta A.M., McArthur D.R., McDermott F.D., McGrath J.S., Malde S., Mirnezami A., Monson J.R.T., Morton J.R., Mullaney T.G., Negoi I., Neto J.W.M., Nguyen B., Nielsen M.B., Nieuwenhuijzen G.A.P., Nilsson P.J., Oliver A., O'Connell P.R., O'Dwyer S.T., Palmer G., Pappou E., Park J., Patsouras D., Pellino G., Peterson A.C., Poggioli G., Proud D., Quinn M., Quyn A., Radwan R.W., Rasheed S., Rasmussen P.C., Regenbogen S.E., Renehan A., Rocha R., Rochester M., Rohila J., Rothbarth J., Rottoli M., Roxburgh C., Rutten H.J.T., Ryan E.J., Safar B., Sagar P.M., Sahai A., Saklani A., Sammour T., Sayyed R., Schizas A.M.P., Schwarzkopf E., Scripcariu V., Selvasekar C., Shaikh I., Shellawell G., Shida D., Simpson A., Smart N.J., Smart P., Smith J.J., Solbakken A.M., Solomon M.J., Sorensen M.M., Steele S.R., Steffens D., Stitzenberg K., Stocchi L., Stylianides N.A., Swartling T., Sumrien H., Sutton P.A., Swartking T., Tan E.J., Taylor C., Tekkis P.P., Teras J., Thurairaja R., Toh E.L., Tsarkov P., Tsukada Y., Tsukamoto S., Tuech J.J., Turner W.H., Tuynman J.B., van Ramshorst G.H., van Zoggel D., Vasquez-Jimenez W., Verhoef C., Vizzielli G., Voogt E.L.K., Uehara K., Wakeman C., Warrier S., Wasmuth H.H., Weber K., Weiser M.R., Wheeler J.M.D., Wild J., Wilson M., Wolthuis A., Yano H., Yip B., Yip J., Yoo R.N., Winter D.C., Surgery, Dudurych, I., Kelly, M. E., Aalbers, A. G. J., Abdul Aziz, N., Abecasis, N., Abraham-Nordling, M., Akiyoshi, T., Alberda, W., Albert, M., Andric, M., Angenete, E., Antoniou, A., Auer, R., Austin, K. K., Aziz, O., Baker, R. P., Bali, M., Baseckas, G., Bebington, B., Bedford, M., Bednarski, B. K., Beets, G. L., Berg, P. L., Beynon, J., Biondo, S., Boyle, K., Bordeianou, L., Bremers, A. B., Brunner, M., Buchwald, P., Bui, A., Burgess, A., Burger, J. W. A., Burling, D., Burns, E., Campain, N., Carvalhal, S., Castro, L., Caycedo-Marulanda, A., Chan, K. K. L., Chang, G. J., Chew, M. H., Chok, A. K., Chong, P., Christensen, H. K., Clouston, H., Codd, M., Collins, D., Colquhoun, A. J., Corr, A., Coscia, M., Coyne, P. E., Creavin, B., Croner, R. S., Damjanovic, L., Daniels, I. R., Davies, M., Davies, R. J., Delaney, C. P., Wilt, J. H. W., Denost, Q., Deutsch, C., Dietz, D., Domingo, S., Dozois, E. J., Duff, M., Eglinton, T., Enrique-Navascues, J. M., Espin-Basany, E., Evans, M. D., Fearnhead, N. S., Flatmark, K., Fleming, F., Frizelle, F. A., Gallego, M. A., Garcia-Granero, E., Garcia-Sabrido, J. L., Gentilini, L., George, M. L., George, V., Ghouti, L., Giner, F., Ginther, N., Glynn, R., Golda, T., Griffiths, B., Harris, D. A., Hagemans, J. A. W., Hanchanale, V., Harji, D. P., Helewa, R. M., Heriot, A. G., Hochman, D., Hohenberger, W., Holm, T., Hompes, R., Jenkins, J. T., Kaffenberger, S., Kandaswamy, G. V., Kapur, S., Kanemitsu, Y., Kelley, S. R., Keller, D. S., Khan, M. S., Kiran, R. P., Kim, H., Kim, H. J., Koh, C. E., Kok, N. F. M., Kokelaar, R., Kontovounisios, C., Kristensen, H. O., Kroon, H. M., Kusters, M., Lago, V., Larsen, S. G., Larson, D. W., Law, W. L., Laurberg, S., Lee, P. J., Limbert, M., Lydrup, M. L., Lyons, A., Lynch, A. C., Mantyh, C., Mathis, K. L., Margues, C. F. S., Martling, A., Meijerink, W. J. H. J., Merkel, S., Mehta, A. M., Mcarthur, D. R., Mcdermott, F. D., Mcgrath, J. S., Malde, S., Mirnezami, A., Monson, J. R. T., Morton, J. R., Mullaney, T. G., Negoi, I., Neto, J. W. M., Nguyen, B., Nielsen, M. B., Nieuwenhuijzen, G. A. P., Nilsson, P. J., Oliver, A., O'Connell, P. R., O'Dwyer, S. T., Palmer, G., Pappou, E., Park, J., Patsouras, D., Pellino, G., Peterson, A. C., Poggioli, G., Proud, D., Quinn, M., Quyn, A., Radwan, R. W., Rasheed, S., Rasmussen, P. C., Regenbogen, S. E., Renehan, A., Rocha, R., Rochester, M., Rohila, J., Rothbarth, J., Rottoli, M., Roxburgh, C., Rutten, H. J. T., Ryan, E. J., Safar, B., Sagar, P. M., Sahai, A., Saklani, A., Sammour, T., Sayyed, R., Schizas, A. M. P., Schwarzkopf, E., Scripcariu, V., Selvasekar, C., Shaikh, I., Shellawell, G., Shida, D., Simpson, A., Smart, N. J., Smart, P., Smith, J. J., Solbakken, A. M., Solomon, M. J., Sorensen, M. M., Steele, S. R., Steffens, D., Stitzenberg, K., Stocchi, L., Stylianides, N. A., Swartling, T., Sumrien, H., Sutton, P. A., Swartking, T., Tan, E. J., Taylor, C., Tekkis, P. P., Teras, J., Thurairaja, R., Toh, E. L., Tsarkov, P., Tsukada, Y., Tsukamoto, S., Tuech, J. J., Turner, W. H., Tuynman, J. B., van Ramshorst, G. H., van Zoggel, D., Vasquez-Jimenez, W., Verhoef, C., Vizzielli, G., Voogt, E. L. K., Uehara, K., Wakeman, C., Warrier, S., Wasmuth, H. H., Weber, K., Weiser, M. R., Wheeler, J. M. D., Wild, J., Wilson, M., Wolthuis, A., Yano, H., Yip, B., Yip, J., Yoo, R. N., and Winter, D. C.

Subjects
Artificial intelligence, medicine.medical_treatment, Machine learning, computer.software_genre, Logistic regression, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], SDG 3 - Good Health and Well-being, Medicine, Humans, Pelvic exenteration, Receiver operating characteristic, Artificial neural network, business.industry, Rectal Neoplasms, Deep learning, Gastroenterology, Prognosis, pelvic exenteration, Support vector machine, machine learning, Test set, colorectal surgery, Neoplasm Recurrence, Local, business, computer, Predictive modelling, artificial neural network
Abstract

Aim: We aim to compare machine learning with neural network performance in predicting R0 resection (R0), length of stay >14days (LOS), major complication rates at 30days postoperatively (COMP) and survival greater than 1 year (SURV) for patients having pelvic exenteration for locally advanced and recurrent rectal cancer. Method: A deep learning computer was built and the programming environment was established. The PelvEx Collaborative database was used which contains anonymized data on patients who underwent pelvic exenteration for locally advanced or locally recurrent colorectal cancer between 2004 and 2014. Logistic regression, a support vector machine and an artificial neural network (ANN) were trained. Twenty per cent of the data were used as a test set for calculating prediction accuracy for R0, LOS, COMP and SURV. Model performance was measured by plotting receiver operating characteristic (ROC) curves and calculating the area under the ROC curve (AUROC). Results: Machine learning models and ANNs were trained on 1147 cases. The AUROC for all outcome predictions ranged from 0.608 to 0.793 indicating modest to moderate predictive ability. The models performed best at predicting LOS >14days with an AUROC of 0.793 using preoperative and operative data. Visualized logistic regression model weights indicate a varying impact of variables on the outcome in question. Conclusion: This paper highlights the potential for predictive modelling of large international databases. Current data allow moderate predictive ability of both complex ANNs and more classic methods.

Published
2020

47. Team dynamics and clinician's experience influence decisionmaking during Upper-GI multidisciplinary team meetings: A multiple case study.

Author

Luijten, J. C. H. B. M., Westerman, M. J., Nieuwenhuijzen, G. A. P., Walraven, J. E. W., Sosef, M. N., Beerepoot, L. V., van Hillegersberg, R., Muller, K., Hoekstra, R., Bergman, J. J. G. H. M., Siersema, P. D., van Laarhoven, H. W. M., Rosman, C., Brom, L., Vissers, P. A. J., and Verhoeven, R. H. A.

Subjects
MEDICAL personnel, SEMI-structured interviews, THEMATIC analysis, TEAMS
Abstract

Background: The probability of undergoing treatment with curative intent for esophagogastric cancer has been shown to vary considerately between hospitals of diagnosis. Little is known about the factors that attribute to this variation. Since clinical decision making (CDM) partially takes place during an MDTM, the aim of this qualitative study was to assess clinician's perspectives regarding facilitators and barriers associated with CDM during MDTM, and second, to identify factors associated with CDM during an MDTM thatmay potentially explain differences in hospital practice. Methods: A multiple case study design was conducted. The thematic content analysis of this qualitative study, focused on 16 MDTM observations, 30 semistructured interviews with clinicians and seven focus groups with clinicians to complement the collected data. Interviews were transcribed ad verbatim and coded. Results: Factors regarding team dynamics that were raised as aspects attributing to CDM were clinician's personal characteristics such as ambition and the intention to be innovative. Clinician's convictions regarding a certain treatment and its outcomes and previous experiences with treatment outcomes, and team dynamics within the MDTM influenced CDM. In addition, a continuum was illustrated. At one end of the continuum, teams tended to be more conservative, following the guidelines more strictly, versus the opposite in which hospitals tended towards a more invasive approach maximizing the probability of curation. Conclusion: This study contributes to the awareness that variation in team dynamics influences CDM during an MDTM. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

48. Fit-for-Discharge Criteria after Esophagectomy: An International Expert Delphi Consensus

Author

Mueller, P. C., Kapp, J. R., Vetter, D., Bonavina, L., Brown, W., Castro, S., Cheong, E., Darling, G. E., Egberts, J., Ferri, L., Gisbertz, S. S., Gockel, I, Grimminger, P. P., Hofstetter, W. L., Hoelscher, A. H., Low, D. E., Luyer, M., Markar, S. R., Moenig, S. P., Moorthy, K., Morse, C. R., Mueller-Stich, B. P., Nafteux, P., Nieponice, A., Nieuwenhuijzen, G. A. P., Nilsson, M., Palanivelu, C., Pattyn, P., Pera, M., Rasanen, J., Ribeiro, U., Rosman, C., Schroeder, W., Sgromo, B., van Berge Henegouwen, M., I, van Hillegersberg, R., van Veer, H., van Workum, F., Watson, D., I, Wijnhoven, B. P. L., Gutschow, C. A., Mueller, P. C., Kapp, J. R., Vetter, D., Bonavina, L., Brown, W., Castro, S., Cheong, E., Darling, G. E., Egberts, J., Ferri, L., Gisbertz, S. S., Gockel, I, Grimminger, P. P., Hofstetter, W. L., Hoelscher, A. H., Low, D. E., Luyer, M., Markar, S. R., Moenig, S. P., Moorthy, K., Morse, C. R., Mueller-Stich, B. P., Nafteux, P., Nieponice, A., Nieuwenhuijzen, G. A. P., Nilsson, M., Palanivelu, C., Pattyn, P., Pera, M., Rasanen, J., Ribeiro, U., Rosman, C., Schroeder, W., Sgromo, B., van Berge Henegouwen, M., I, van Hillegersberg, R., van Veer, H., van Workum, F., Watson, D., I, Wijnhoven, B. P. L., and Gutschow, C. A.

Abstract

There are no internationally recognized criteria available to determine preparedness for hospital discharge after esophagectomy. This study aims to achieve international consensus using Delphi methodology. The expert panel consisted of 40 esophageal surgeons spanning 16 countries and 4 continents. During a 3-round, web-based Delphi process, experts voted for discharge criteria using 5-point Likert scales. Data were analyzed using descriptive statistics. Consensus was reached if agreement was >= 75% in round 3. Consensus was achieved for the following basic criteria: nutritional requirements are met by oral intake of at least liquids with optional supplementary nutrition via jejunal feeding tube. The patient should have passed flatus and does not require oxygen during mobilization or at rest. Central venous catheters should be removed. Adequate analgesia at rest and during mobilization is achieved using both oral opioid and non-opioid analgesics. All vital signs should be normal unless abnormal preoperatively. Inflammatory parameters should be trending down and close to normal (leucocyte count <= 12G/l and C-reactive protein <= 80 mg/dl). This multinational Delphi survey represents the first expert-led process for consensus criteria to determine 'fit-for-discharge' status after esophagectomy. Results of this Delphi survey may be applied to clinical outcomes research as an objective measure of short-term recovery. Furthermore, standardized endpoints identified through this process may be used in clinical practice to guide decisions regarding patient discharge and may help to reduce the risk of premature discharge or prolonged admission.

Published
2021

49. Improved response rate in patients with prognostically poor locally advanced rectal cancer after treatment with induction chemotherapy and chemoradiotherapy when compared with chemoradiotherapy alone: A matched case-control study

Author

Voogt, E. L. K., Voogt, E. L. K., Schaap, D. P., Berg, K. van den, Nieuwenhuijzen, G. A. P., Bloemen, J. G., Creemers, G. J., Willems, J., Cnossen, J. S., Peulen, H. M. U., Nederend, J., van Lijnschoten, G., Burger, J. W. A., Rutten, H. J. T., Voogt, E. L. K., Voogt, E. L. K., Schaap, D. P., Berg, K. van den, Nieuwenhuijzen, G. A. P., Bloemen, J. G., Creemers, G. J., Willems, J., Cnossen, J. S., Peulen, H. M. U., Nederend, J., van Lijnschoten, G., Burger, J. W. A., and Rutten, H. J. T.

Abstract

Introduction: The addition of induction chemotherapy (ICT) to neoadjuvant chemoradiotherapy (CRT) has the potential to improve outcomes in patients with locally advanced rectal cancer (LARC). However, patient selection is essential to prevent overtreatment. This study compared the complete response (CR) rate after treatment with and without ICT of LARC patients with prognostically poor characteristics. Methods: All LARC patients who were treated with neoadjuvant CRT, whether or not preceded by ICT, and who underwent surgery or were considered for a wait-and-see strategy between January 2016 and March 2020 in the Catharina Hospital Eindhoven, were retrospectively selected. LARC was defined as any T4 tumour, or a T2/T3 tumour with extramural venous invasion and/or tumour deposits and/or N2 lymph node status, and/or mesorectal fascia involvement (T3 tumours only). Case-control matching was per -formed based on the aforementioned characteristics. Results: Of 242 patients, 178 (74%) received CRT (CRT-group) and 64 patients (26%) received ICT followed by CRT (ICT-group). In the ICT-group, 3 patients (5%) did not receive the minimum of three cycles. In addition, in this selected cohort, compliance with radiotherapy was 100% in the ICT-group and 97% in the CRT-group. The CR rate was 30% in the ICT-group and 15% in the CRT-group (p = 0.011). After case-control matching, the CR rate was 28% and 9%, respectively (p = 0.013). Conclusion: Treatment including ICT seemed well tolerated and resulted in a high CR rate. Hence, this treatment strategy may facilitate organ preservation and improve survival in LARC patients with prog-nostically poor characteristics. (c) 2021 Elsevier Ltd, BASO -The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Published
2021

50. The eHealth self-management application ‘Oncokompas’ that supports cancer survivors to improve health-related quality of life and reduce symptoms:which groups benefit most?

Author

van der Hout, A., Holtmaat, K., Jansen, F., Lissenberg-Witte, B. I., van Uden-Kraan, C. F., Nieuwenhuijzen, G. A.P., Hardillo, J. A., Baatenburg de Jong, R. J., Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J.E., Bosscha, K., van den Brekel, M. W.M., Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, I., van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E.J., Leemans, C. R., Zijlstra, J. M., Cuijpers, P., van de Poll-Franse, L. V., Verdonck-de Leeuw, I. M., van der Hout, A., Holtmaat, K., Jansen, F., Lissenberg-Witte, B. I., van Uden-Kraan, C. F., Nieuwenhuijzen, G. A.P., Hardillo, J. A., Baatenburg de Jong, R. J., Tiren-Verbeet, N. L., Sommeijer, D. W., de Heer, K., Schaar, C. G., Sedee, R. J.E., Bosscha, K., van den Brekel, M. W.M., Petersen, J. F., Westerman, M., Honings, J., Takes, R. P., Houtenbos, I., van den Broek, W. T., de Bree, R., Jansen, P., Eerenstein, S. E.J., Leemans, C. R., Zijlstra, J. M., Cuijpers, P., van de Poll-Franse, L. V., and Verdonck-de Leeuw, I. M.

Abstract

Background: Oncokompas is a web-based self-management application that supports cancer survivors to monitor their health-related quality of life (HRQOL) and symptoms, and to obtain personalised feedback and tailored options for supportive care. In a large randomised controlled trial among survivors of head and neck cancer, colorectal cancer, and breast cancer and (non-)Hodgkin lymphoma, Oncokompas proved to improve HRQOL, and to reduce several tumour-specific symptoms. Effect sizes were however small, and no effect was observed on the primary outcome patient activation. Therefore, this study aims to explore which subgroups of cancer survivors may especially benefit from Oncokompas. Materials and methods: Cancer survivors (n = 625) were randomly assigned to the intervention group (access to Oncokompas, n = 320) or control group (6 months waiting list, n = 305). Outcome measures were HRQOL, tumour-specific symptoms, and patient activation. Potential moderators included socio-demographic (sex, age, marital status, education, employment), clinical (tumour type, stage, time since diagnosis, treatment modality, comorbidities), and personal factors (self-efficacy, personal control, health literacy, Internet use), and patient activation, mental adjustment to cancer, HRQOL, symptoms, and need for supportive care, measured at baseline. Linear mixed models were performed to investigate potential moderators. Results: The intervention effect on HRQOL was the largest among cancer survivors with low to moderate self-efficacy, and among those with high personal control and those with high health literacy scores. Cancer survivors with higher baseline symptom scores benefitted more on head and neck (pain in the mouth, social eating, swallowing, coughing, trismus), and colorectal cancer (weight) specific symptoms. Discussion: Oncokompas seems most effective in reducing symptoms in head and neck cancer and colorectal cancer survivors who report a higher burden of tumour-specific sym

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results